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Abstract 
Although the critical role of the small GTPases Ras and Ral in oncogenesis has 
been well documented, much remains to be investigated about the molecular mechanism 
by which these GTPases regulate malignant transformation. The work under this thesis 
made two major contributions to this field. The first is the discovery that K-Ras, RalA 
and/or RalB are required for the maintenance of the high levels of the anti-apoptotic 
protein survivin in some human cancer cells, and the second is the demonstration that 
down regulation of K-Ras, RalA and/or RalB, but not Raf-1 or Akt1/2, stabilizes the 
tumor suppressor p53 and reactivates it to inhibit malignant transformation in human 
cancer cells with mutant K-Ras and wild type p53. Here we found that depletion of K-
Ras leads to decreased survivin levels in human cancer cells that harbor mutant K-Ras 
but not those with wild type Ras. The mechanism by which this occurs involves 
ubiquitination and subsequent proteasome-mediated degradation of survivin. The 
presence of mutant K-Ras alone was not sufficient to predict the effects of RalA/B 
depletion on survivin levels. Indeed, depletion of RalA and/or RalB reduces survivin 
levels in human cancer cells with wild type p53 and mutant K-Ras, but not in those with 
mutant p53 and/or wild type K-Ras. The functional relevance of these findings to 
malignant transformation was further supported by the demonstration that compromising 
the expression of survivin by siRNA leads to reduction of mutant K-Ras-driven invasion 
and anchorage-independent growth. Furthermore, in this thesis, we have discovered that 
down regulation of K-Ras, RalA and/or RalB using siRNA leads to increased levels of 
xi 
 
functional p53 that is capable of regulating its target genes. The mechanism by which 
depleting K-Ras, RalA and RalB increases the levels of p53 involves an increase in the 
half-life of the p53 protein concurrent with an increase in the phosphorylation of serine-
15 of p53, a marker of p53 stability. Finally, we demonstrated that depletion of K-Ras, 
RalA and/or RalB interferes with cell cycle progression, anchorage-independent growth 
and invasion in a p53-dependent manner. In summary, the studies suggest that mutant K-
Ras contributes to the maintenance of the aberrantly-high survivin levels by regulating its 
stability, and that the ability of mutant K-Ras to induce malignant transformation is, at 
least in part, dependent of these high levels of survivin.  The work of this thesis also 
suggests that the expression of K-Ras, RalA and/or RalB proteins is critical to maintain 
low levels of p53, and that down regulation of these GTPases reactivates p53 by 
significantly enhancing its stability, and this contributes to suppression of malignant 
transformation. 
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Chapter 1 
 
Introduction 
Cancer versus normal cells 
The transformation of normal cells to cancer cells is thought to arise from gradual 
accumulation of multiple genetic alterations such as mutations, chromosomal 
translocations and amplifications. These genetic alterations can lead to activation of 
cancer-causing genes (oncogenes) such as Ras GTPases and/or inactivation of tumor 
suppressor genes such as p53. Pioneering work over the last 3 decades documented that a 
single genetic alteration is not sufficient to elicit full-blown transformed phenotype. For 
example, Fearon and Vogelstein’s elegant work led to the discovery that colon cancer 
develops as a result of successive genetic alterations that are involved in driving 
malignant transformation or inhibiting tumor suppression
1
. These genetic alterations lead 
to deregulated signal transduction pathways that in turn result in several hallmarks of 
cancers such as  apoptosis evasion, invasion, metastasis, resistance to growth suppressors, 
sustained proliferative signals, immortality, angiogenesis, evasion of immune destruction 
and deregulated cellular energetic
2
. 
Many of the altered genes in cancer cells are intimately involved in signal 
transduction pathways that mediate these hallmarks of cancer. For example, mutations in 
the Ras gene persistently activate Raf/Mek/Erk, Pi3K/Akt and RalGDS/Ral signaling 
pathways that mediate many of the hallmarks of cancer including sustained proliferation, 
2 
 
survival, angiogensis and metastasis
2
. Up-regulation of the inhibitors of apoptosis (IAPs) 
such as survivin and the anti-apoptotic BCL-2 family proteins such as Bcl-xL and Mcl-1 
contribute to apoptosis evasion. Amplification of telomerase enables immortality whereas 
mutations and/or deletions of the tumor suppressors p53 and RB lead to deregulation of 
the cell cycle and enable cells to proliferate continuously
2
. Furthermore, up regulation of 
VEGF-A enables the formation of new tumor blood vessels, loss of E-cadherin promotes 
invasion and metastasis, up-regulation of GLUT-4 increase glucose import into the 
cytoplasm and  reprogramming of energy metabolism and up-regulation of TGF-β 
enables cancer cells to evade immune system by disabling natural killer (NK) cells
2
. 
While the above mentioned mechanism are cited separately, it needs to be emphasized 
that the complex crosstalk among the various aberrant signal transduction pathways is 
often required for normal cells to trespass the normal control mechanism, acquire certain 
hallmarks of cancer and eventually become fully transformed.  
Ras, Ral and p53 
Ras 
Ras is a small GTPase that cycle between GTP and GDP binding states. Active 
Ras is GTP bound and capable of transducing signals from surface receptors to the 
nucleus to regulate a wide range of cellular processes including differentiation, survival 
and motility
3
. Mutations of Ras are among the most frequently observed mutations in 
human cancer. The mutant version of Ras is defective of its intrinsic GTPase activity and 
becomes GTP-locked Ras which enables it to stay engaged to its downstream effectors 
persistently, and drive malignant transformation
3
. This prompted many over the last 
several decades to target Ras directly and indirectly to discover novel anti-cancer drugs. 
3 
 
For example, attempts to identify small molecule that can bind Ras either at the GTP 
binding site, effector site or allosteric sites and induce a conformational change to reverse 
the GTP-lock to the GDP inactive form of Ras were unsuccessful; although renewed 
efforts in this area have yielded encouraging results recently
4, 5
. 
An indirect approach to inhibit Ras function that has been investigated 
extensively is to prevent Ras from associating with the plasma membrane
6
. Ras proteins 
undergo prenylation, a type of posttranslational modification, to be able to localize in the 
membrane. This localization of Ras on the membrane is required for its activation as well 
as for Ras to find and bind its downstream effectors. Previous studies have shown that 
this post-translational modification is required for the cancer-causing activity of Ras. 
Prenylation is defined as the attachment of a geranylgeranyl or a farnesyl group to the 
cysteine of the CAXX box at the C-terminus of Ras by either geranylgeranyl transferase-
1 (GGT-1) or farnesyl transferase (FT). Since these enzymes transfer the prenyl group to 
Ras, it was reasonable to inhibit these enzymes to prevent Ras from localizing to the 
membrane. Subsequently, several potent and selective geranylgeranyl transferase 
inhibitors (GGTIs) and farnesyl transferase inhibitors (FTIs) have been developed and 
shown to inhibit Ras membrane association, Ras-driven oncogenic signaling and 
malignant transformation in vitro and tumor growth in mouse models
6
 . Several FTIs 
have been tested clinically and one GGTI has recently entered clinical trials
6.
 
Unfortunately, the outstanding pre clinical results with FTIs have not translated into 
efficacy in human clinical trials, and so far there is no FDA approved FTI that is used in 
the clinic. The reasons for this are not well understood.  However, the fact that FT has 
several hundreds of potential substrates (the human genome encodes about 500 proteins 
4 
 
that harbor a CAXX box at their C-termini) may contribute to this
6
.  Indeed, at present it 
is not know yet which farnesylated proteins are some tumors addicted to. Another reason 
may be related to alternative prenylation. For example, among the isoforms of Ras that 
are implicated in tumorigenesis, H-Ras is known to undergo farnesylation exclusively, 
however, N-Ras and K-Ras have been shown to undergo geranylgeranylation when 
human cancer cells are challenged with FTIs
7
 . 
Another indirect approach to inhibit the function of Ras is to target downstream 
effectors that have been implicated in cancer. For example, Raf-1 was the first identified 
effecter of Ras known to mediate Ras driven malignant transformation. Subsequently, 
several Raf-1 kinase inhibitors were developed and many of them showed anti-tumor 
activity, however in some tumors, despite complete inhibition of Raf-1 kinase activity, 
the tumors still progressed, suggesting existence of other important downstream effectors 
that transduce Ras driven transformation
8, 9
.  Indeed subsequent studies identified the 
Pi3K/Akt, and RalGDS/Ral and other downstream signaling pathways as critical 
effectors that mediate Ras-driven malignant transformation. To date, there are several 
inhibitors of these pathways that are in clinical trials
6
. Ras is known to activate more than 
20 downstream effectors and these have been shown to be involved in different 
physiological functions of the cell, so the challenge at this moment is to identify the 
critical effecters of Ras that human tumors are addicted to. Recent studies have tried to 
address this issue using large scale RNAi screen. Using different cell lines that harbor 
mutant or wt-K-Ras genes, several target genes were identified, the depletion of which 
resulted in selective killing of cancer cells that harbor mutant but not wt K-Ras
10-12
. 
Nonetheless, these studies identified different genes in different cell lines and there was 
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no consensus gene the depletion of which induces selective killing of cancer cell with K-
Ras mutation. To date, studies that aim at identifying the critical downstream effectors of 
mutant K-Ras continue to be under intense investigation.  
Ral  
Ral (Ras like) proteins are small GTPases that belong to the Ras family of G 
proteins
13
.  As the name indicated, Ral GTPases were first identified when searching for 
Ras like genes using oligonucleotide probes that correspond to a sequence of seven 
amino acid that are conserved in Ras
14
. The cDNA library screen from immortalized 
simian B-lymphocyte screen identified RalA as a Ras related gene. Using the simian 
RalA sequence human RalA and RalB were identified from a phechromocytoma library. 
Both RalA and RalB are exclusively geranygeranylated by GGT-1 and this 
geranylgeranylation is required for their localization and function
15
.  
Initially, Ral GTPases didn’t get wide attention in cancer because they were found 
to have only minor role in Ras driven tumor formation in rodent cells. Later, however, the 
Ral guanine exchange factor RalGDS, which activates RalA and RalB, was shown to 
directly bind Ras and to play a critical role in Ras-driven tumorigenesis in human cancer 
cells of epithelial as well as of fibroblast origin
16-20
. 
Activation of Ral 
Like all small G proteins Ral GTPases are GTP/GDP binding proteins that are 
active when bound to GTP and inactive when bound to GDP
21
 . Ral GTPases can be 
activated by two major mechanisms: Ras-dependent
22-24
 and Ras-independent 
activation
25-27
.  
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Ras-dependent activation of Ral 
Activated Ras can bind directly to several proteins and subsequently induce 
activation of numerous downstream effecter pathways that modulate a variety of 
biological functions. Activation of the Raf/Mek/Erk, Pi3K/Akt and RalGDS/Ral 
pathways through direct binding of their up-stream activators has been previously 
described
3
 (see figure 1 below).  
 
Guanine nucleotide exchange factors (GEFs) such as Rgl, Rlf and RalGDS
28, 29
 
can activate Ral proteins. Ras activate Ral proteins by binding RalGDS. Structurally 
RalGDS has a Ras binding domain (RBD) at its C terminus 
30
, 
31
 which enables it to 
interact with Ras.  When activated by Ras, RalGDS can then exchange GDP to GTP on 
Ral. RBD of RalGDS is critical for Ras-induced activation of RalGDS but activation of 
PP
Ras
GEF
R
a
s
Pi3K/Akt Raf/Mek/Erk RalGDS
RalGTPase
RalA
RalB
NFkB RalBP1
Cyclin D CDC42/Rac
c-src
pSTAT3
Filamin A Exoc2
GAP
Exocyst
regulation
Proliferation/ 
transformation
Activation of 
transcription 
Elicit actin rich 
filapods
 
Figure 1. Activation of RalGTPases and their downstream effectors. Upon 
activation, RalGDS activates RalA and RalB which in turn modulate  
downstream effectors that are involved in the regulation of different cellular 
processes.  
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RalGDS in the absence of RBD domain of RalGDS has also been reported
25, 26
. 
Linnemann et al show that, RalGDS that lack RBD but artificially targeted to the 
membrane, can still be activated by Ras
12
. 
Ras-independent activation of Ral 
Activation of Ral independent of Ras has also been described. Hofer et al
25
 show 
that treating Rat-2 cells with Ca
2+ 
activated Ral independently of Ras. The result show 
that inhibition of  phospholipase C (PLC) blocks Ca
2+
 induced activation of Ral, implying 
that PLC was required for Ca
2+
 induced activation of Ral proteins
25
. As suggested by 
Hofer et al, the mechanism by which Ca
2+
 activates Ral could be through phosphorylation 
of RalGDS by Calcuim-Calmodulin dependent kinase II or through direct interaction of 
Ca
2+
 with Ral. RalA has calmodulin binding site at its C terminus, and the binding of 
Ca
2+
 facilitate GTP binding to the RalA protein. For Ca
2+
 dependent activation to occur 
geranylgeranylation of Ral and calmodulin interaction are required 
32
. Different studies 
have also shown that RalGEF undergo posttranslational modification that enables it to 
localize in the membrane where it can be activated 
33
 . RalGEF can also be stimulated 
upon association with PI3-K-dependent kinase 1  (PDK1)
34
. The activation of Ral GEF 
activity by PDK1 doesn’t involve its kinase activity, but rather depends on the  Epidermal 
Growth Factor (EGF)-induced complex formation between PDK-1 and the N terminus of 
RalGDS which relieves the auto inhibitory effect on the catalytic domain of RalGDS.  
Functions of activated Ral 
RalA and RalB are two isoforms that share ~85% overall amino acid sequence 
identity and ~100% sequence identity in sequences important for effectors binding
14
. 
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Once activated by RalGEF, they bind to different or similar molecules that play important 
roles in cell cycle and transformation
35
.  
Since RalA and RalB share identical effector binding domain,  the two Ral 
proteins would be expected to bind to similar molecules and elicit similar functions but 
studies so far show that the two Ral proteins do not necessarily bind to same molecules or 
elicit same biological outcomes. In fact there are situation where the two proteins are 
shown to bind to different effectors and to elicit antagonistic functions.  
 
Significance of Ral protein in human tumorigenesis 
Evidence for the importance of Ral in human tumorigenesis started to emerge 
when RalGEF was identified as direct interacting protein of Ras and when Ral GDS was 
shown to be required for Ras-driven malignant transformation
36
. Furthermore, other 
studies showed that activated Ral was found in human pancreatic cancer cells
35
 where the 
 
Figure 2. Role of RalA and RalB in cancer. The small GTPases RalA and 
RalB display distinct as well as overlapping functions in cancer.  
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frequency of K-Ras mutation is also high. Moreover, depletion of Ral protein reduced 
Ras ability to transform cells. Similarly, in vivo studies demonstrated that mice deficient 
of RALGDS, which is one of Ral GEFs, were developmentally normal but showed 
reduced skin tumor growth driven by oncogenic H-Ras 
16
. A very recent study showed 
that deletion of both RalA and RalB genes inhibit tumor formation
37
.  Other studies also 
showed RalA to be the target of known the tumor suppressor phosphatase, protein 
phosphates 2A (PP2A)
38, 39
. Lim et al. also showed that stable knockdown of RalA in 
pancreatic cancer cells that harbor mutant K-Ras reduces anchorage independent growth 
in soft agar, which further support the role of Ral in transformation
35
. All in all, these 
findings suggest deregulation and significant role of Ral in cancer. 
Role of Ral in cell survival 
Loss of function studies have shown that depletion of RalB but not RalA initiates 
programmed cell death in cancer cell line but there was no effect in normal cell line or 
immortalized cell lines.  Interestingly, when RalA and RalB are depleted together, this 
reverses the death phenotype seen when only RalB is depleted in cancer cells and 
immortalized cells that harbor oncogenic H-Ras. This suggested that the two proteins 
function antagonistically to regulate cell survival
40
.  
Akt/ protein kinase B (PKB) is one of the survival protein downstream of Ras. 
Depletion of RalGDS by RNAi blocks insulin- as well as EGF-induced phosphorylation 
of Akt at T-308 and S-473. It is speculated that RalGDS activates Akt by acting as a 
scaffold to bring Akt closer to its activator PDK1. In fact shRNA depletion of RalGDS 
sensitizes cells to drug-induced apoptosis
41
. These studies suggest a role of RalGDS in 
survival through its ability to modulate Akt activation.  
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Role of Ral in cell migration, invasion and metastasis 
Another hallmark of cancer is invasion and metastasis. The ability of cancer cells 
to invade adjacent tissue and migrate to distant site constitute one of the worst phenotype 
of cancer pathogenesis. Therefore, the ability of cells to move helps them to metastasize 
to distant site. While RalA but not RalB is critical for Ras driven transformation, RalB 
plays critical a role in cell migration. While Rosse et al
42
 and Oxford et al.
43
 show that 
depletion of RalB but not RalA by siRNA in UMUC-3 (bladder cancer cell line) and DU 
145 (prostate cancer cell line)  reduces migration, Lim et al 
35
 show that depletion of 
RalA also reduce migration in some pancreatic cancer cells, suggesting the role of Ral in 
cell migration could be cell line specific. Nonetheless RalB seem to show dominant effect 
in migration. In addition, NIH-3T3 cells that were transformed by Ras effecter mutant 
that activate Ral (Ras12V37G) promotes invasion and this was antagonized by over 
expressing dominant negative RalB
44
.  High level of activated RalA was also found more 
in metastatic cell than their counterpart non metastatic cells
33
 suggesting the role of 
activated RalA in this cancer hallmark.  
In-vivo study show that HEK cells transformed by mutant H-Ras form fewer 
number of lung metastatic nodules when stably transfected with shRNA to RalA. 
Furthermore, even though RalB was dispensable for tumor establishment, cells where 
RalB was knockdown by shRNA had  significantly impaired metastasis 
35
. Although 
RalA depletion reduces oncogenic Ras driven metastasis, dominant negative RalA had 
minimum effect on metastasis in Ras12V37G
45
. This suggests  that RalGTPases require 
additional proteins and/or molecules to promote metastasis.  
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Role of Ral in cell cycle 
The ability of the body to replace old and dead cells largely depends on cell cycle. 
This activity is highly regulated in order to avoid uncontrolled proliferation. Cancer cells 
usually become insensitive or evade normal cell cycle control. Cell cycle checkpoints are 
important to ensure the completion of previously initiated cell cycle activity before 
proceeding with the subsequent steps. Like other signaling protein, Ral proteins have also 
been shown to play roles in cell cycle progression.  
The two Ral proteins seem to work in collaboration for this activity. RalA 
mobilizes the exocyst, to the cytokinetic furrow during the early stage of cytokinesis and 
RalB pulls the complex toward the midbody of the cell and drives abscission to complete 
cytokinesis
46
. RalA and RalB share Exo84 and PLD1 as effectors of cytokinesis but RalA 
additionally uses Sec5 for early recruitment of exocyst component.   
CDK1 is the major mitotic kinase and is regulated by different inhibitory as well 
as activating kinases and also phosphatases. The Ras/Ral signaling pathway has been 
shown to decrease the inhibitory phosphorylation of cdc2 at Y15 after DNA damage 
induced by chemicals. This suggests that Ras/Ral signaling contributes to the activation 
of CDK1 and plays a role in mitosis.   
Activation of the Ras/RasGDS/Ral pathway inhibits G2 arrest following DNA 
damage
47
. This was demonstrated by showing that dominant negative RalA (N28)  
rescues from the loss of G2 arrest that was seen with cells that have activated Ras and 
that were treated with the DNA damage agent doxorubicin
47
.  
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p53 
p53 is a transcription factor that is known to regulate the expression of different 
genes that are involved in cell cycle as well as apoptosis. It is one of the most frequently 
mutated genes in cancer with ~50% prevalence in human tumor. It was first identified as 
a co-precipitant of SV40-Tag in SV40-infected cells
48
 and since the co-eluate of the 
protein runs at ~53 kilo Dalton in poly-acrylamide gel, the protein was named as p53
49
. 
Since the expression of p53 goes up with SV40 levels in the cell, p53 was considered as 
an oncogene
50
. Subsequently the cloned p53 from transformed cells has been shown to 
cooperate with known oncogenes such as H-Ras to transform cells
51, 52
. Moreover the 
cloned p53 by itself was able to immortalize cells
53
. However, subsequent studies clearly 
demonstrated the tumor suppressive activity of p53 rather than the earlier reported 
oncogenic effect
54, 55
. 
Functionally, p53 has been shown to induce cell cycle arrest at G1 and G2/M 
phases of the cell cycle  as well as apoptosis
56
. It is now widely accepted that the 
molecular mechanism by which p53 accomplish its tumor suppressive activity is through 
transactivation or repression of different genes that are involved in apoptosis as well as 
cell cycle
57, 58
.  
Even though multiple genetical alterations are required for transformation, few 
genes seem to show potent effect at driving or preventing malignant phenotypes, such as 
sustained proliferation, resistance to antigrowth and apoptotic signals. Indeed previous 
studies have shown that, disabling of p53 function cooperate with Ras to transform 
cells
59, 60
. Moreover, using affymetrix microarrays, McMurray et al found a synergistic 
effect on the expression of 95 genes when mutant p53 and Ras are expressed together
61
. 
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The study suggests that p53 and some genes that are regulated by p53 play critical role in 
Ras driven transformation. 
The following are literature gaps filled by the work of this thesis concerning the 
mechanism by which Ral GTPases mediate malignant transformation and the role of the 
tumor suppressor p53 in this process. 
Although Ral has been shown to have significant role in transformation as well as 
in regulating various malignant phenotype, the mechanism by which it regulates these 
phenotypes is not known.  Furthermore, the ability of mt K-Ras to cause cancer depends 
on Ral GTPases, yet the mechanism by which Ral GTPases mediate K-Ras effects is not 
known. Recently, mutant K-Ras was shown to down regulate p53 but whether Ral 
GTPases down regulate p53 is not known.  In this thesis we determined if the expression 
of RalA and/or RalB is required for maintaining low levels of wild type p53 in human 
cancer cells, and whether the expression of RalA/B is required for persistent degradation 
of p53.  This thesis also investigated if Ral GTPases regulate the stability of p53 and if 
the ability of Ral GTPases to contribute to malignant transformation depends on 
suppression of p53. 
Survivin and Apoptosis 
Cell death 
Cells have evolved to respond to proliferative as well as to death signals. Upon 
existence of irreparable abnormality, normal cells are doomed to death. Dying cells are 
characterized by loss of membrane potential, caspase activation, exposure of 
phosphatidylserine residues as well as permeabilization of mitochondrial outer 
membrane. However, since these signals can also be detected in the absence of non-lethal 
14 
 
processes, existence of one signal alone doesn’t represent cell death. So, when is a cell 
considered dead? According to the nomenclature committee on cell death (NCCD) 
cellular death is defined as the presence of the loss of membrane integrity as defined by 
incorporation of vital dyes in vitro, the cell undergo complete fragmentation into discreet 
bodies and engulfment of the corpse by adjacent cell in vivo
62, 63
.  
Different types of cell death have been described based on the morphology of the 
dying cells and the biochemical events that trigger them. Accordingly, four major types 
of cell death exist and these are apoptosis, autophagy, necrosis and cornification. 
Morphologically apoptotic cells are presented as rounded cells, fragmented nucleus, 
retracted pseudopods, blebbing of plasma membrane and also engulfment of apoptotic 
cells by resident phagocytes, in-vivo. Autophagic cells are characterized by massive 
cytoplasmic vaculation as well as accumulation of double-membraned autophagic 
vacuoles. Necrotic cells show swelling of the cytoplasm and its organelles as well as 
rupture of plasma membrane. Cornification is usually seen in skin cells (dermatocytes) 
and it is morphologically characterized by elimination of cytosolic organelles, 
accumulation of lipids in granules, as well as extrusion of lipids in the extracellular space. 
In this thesis, we focus on apoptosis and hence this is further discussed below. 
Apoptosis 
The term apoptosis was first coined by Kerr et al to describe the specific 
morphological change of a dying cell as described above
64
. Apoptosis occurs during 
development, aging as well as normal homeostatic mechanism to maintain the population 
of cells. Furthermore, a cell can undergo apoptosis following irreparable damage or 
abnormality in the cell.  
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The mechanism by which apoptosis is initiated in a cell vary. Some cells express 
death receptors, such as TNF-α or Fas in which binding of ligand to its receptor triggers 
apoptosis. On the other hand, some cells undergo apoptosis by default but it is prevented 
from dying by the binding of growth factor or hormones. In any case, the mechanism by 
which apoptosis occurred is highly complex and sophisticated.  To date, two main 
apoptotic pathways have been identified: Extrinsic and intrinsic apoptotic pathways. The 
extrinsic death pathway is initiated when a death ligand bind to its receptor on cell 
membrane, in contrast, the intrinsic pathway is initiated upon cytochrome C release from 
the mitochondria. Although this two pathways were identified as two separate pathway 
based on how the apoptosis is initiated, subsequent studies show existence of cross-talk 
between the two pathways
65
 (see figure 3).  
Biochemical features of apoptosis 
Caspases are the major enzymes that are involved in apoptosis. Caspases are 
proteolytic enzymes that are capable of degrading proteins by cleaving at aspartic acid 
residues. They are widely expressed in a cell in their inactive form. Upon activation, the 
activated caspases activate other caspases thereby amplifying the apoptotic cascade and 
bringing rapid cell death. To date, 10 major caspases have been identified. They are 
majorly classified as initiator caspases (caspase 2, 8, 9 and 10) because they are known to 
ignite the caspase activation cascade. The other class of caspases are called effecter 
caspases (caspase 3,6, and 7) because they implement the execution phase of the cell 
killing. Finally there are other caspase (caspase 1,4, and 5) referred to as inflammatory 
caspases
61
.  
Other biochemical features of apoptosis is protein cross linking, which is achieved 
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through activation of tissue transglutaminase
66
 as well as phagocytosis as a result of 
expression of cell surface signals, such as phophatidylserine and annexin that send 
signals to phagocytic cells
67
 also exist.  
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Figure3. Activation of intrinsic and extrinsic apoptosis pathways. Intrinsic 
apoptotic pathways can be triggered by many events including DNA damage. 
This in turn results in activation of p53 and subsequent upregulation of pro-
apoptotic Bcl-2 family proteins, which form pores in the mitochondrial 
membrane through which cytochorme-c is released. The released cytochrom-c 
leads to the activation of caspases-9 and -3 and induction of apoptosis. 
Alternatively, apoptosis can be triggered through the extrinsic pathway. In this 
case, a death ligand binds to its receptor activates caspases-8 and -3 and 
induces apoptosis. IAPs can inhibit activation of caspases and this effect could 
be antagonized by SMAC, which is also released from the mitochondria. 
 
17 
 
The extrinsic pathway 
The extrinsic pathway is initiated through activation of a receptor with 
transmembrane receptor binding to its ligand. One of the best characterized receptors is 
the Fas ligand receptor. This receptor has a death domain “DD” on its cytoplasmic 
portion that transmits the death signal from the cell surface to inside the cell
61
. Upon 
binding of a death ligand (FasL) to its receptor (Fas R), the cytoplasmic domain of the 
receptor recruits adaptor proteins (FADD). This adaptor protein then recruits procaspase 
8 and subsequently forms the DISC (death inducing signaling complex) which results in 
auto activation of procaspase-8
61
. Activation of caspase-8 marks the beginning of cell 
death. Activated caspase-8 can then activate caspase-3, which is the executioner of cell 
death.  
The intrinsic pathway 
Unlike the extrinsic pathway, the intrinsic pathway is triggered by events that are 
not dependent on death receptors such as the Fas ligand receptor. The intrinsic pathway 
stimuli include the absence of growth factors or cytokines that normally inhibit cell death.  
Other stimuli are exposure to toxins, radiation or viral infection and other agents that 
stimulate cell death. The intrinsic pathway is also called the mitochondrial apoptotic 
pathway, because the apoptosis executed trough this pathway hinges on mitochondrial 
events. The death stimuli induce changes in the mitochondrial membrane which result in 
pores that allow the release of mitochondrial proteins such as cytochrome-C and Smac-
DIABLO
61
. The cytochorme-C released from the mitochondria binds Apaf-1 and 
procaspase-9 to form the apoptosome
68
, ultimately culminating in the activation of 
caspase-9. Also released from the mitochondrial pores is  Smac/Diablo, a protein that 
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augments apoptosis by inhibiting a family of proteins called Inhibitors of Apoptosis 
(IAPs)
69
.  
Execution phase 
The execution phase is the final step in apoptosis. In this phase caspases 3,6, and 
7 get activated and stimulate different enzymes such as cytoplasmic endonucleases that 
degrades nuclear materials and proteases that degrade different nuclear and cytoskeletal 
proteins
61
.  Among the three executioner caspases, caspase-3 is considered as the most 
important executioner of apoptosis. It gets activated by caspase-9, which is the initiator of 
the intrinsic apoptosis pathway as well as by caspase 8, which is the initiator of the 
extrinsic apoptotic pathway. Once caspase-3 gets activated, it frees CAD from its 
inhibitor (i.e. ICAD). Activated CAD then degrades chromosomal DNA within the nuclei 
and cause degradation of chromosomal DNA, chromatic condensation and disintegration 
of the cell into apoptotic bodies
70
. 
The BCL-2 family proteins 
The Bcl-2 (B-cell lymphoma-2) family members consist of approximately 20 
proteins that are known to regulate apoptosis. While some of these members inhibit 
apoptosis and hence are termed anti-apoptotic, others promote it and hence are termed 
pro-apoptotic proteins.  This family of proteins was first considered as proto-oncogene 
however since they lack the ability to drive cell proliferation, they are now considered as 
proteins that give support to oncogene-driven transformation. Indeed, over expressing 
Myc oncogene along with Bcl-2 has been shown to promote the development of 
lymphoma as well as other types of cancers
71
. 
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The Bcl-2 family proteins have been classified into three groups based on their 
ability to protect or promote apoptosis and the domain they contain in their structure (see 
table below). Structurally, the Bcl-2 family of proteins contain up to four Bcl-2 
homologue (BH) domains that are designated as BH1, BH2, BH3 and BH4
72-74
. Many of 
the anti-apoptotic Bcl-2 family proteins contain all four BH domains while many of the 
pro-apoptotic Bcl-2 family members with multi-BH domain contain the first three BH 
domains (BH1-BH3), the remaining pro-apoptotic proteins harbor only the BH3 domain. 
(see table below) 
Table 1. Classification of Bcl-2 family proteins 
 
Bcl-2 family proteins with multiple BH domains BH3 only proteins  
Anti-apoptotic  Pro-apoptotic  Pro-apoptotic  
Bcl-2 Bax PUMA 
Bcl-XL Bak Bid 
Bcl-W Bok Noxa 
Mcl-1  Bad 
Bcl-B  Blk 
A1  Bim 
  HRK 
  BMF 
 
 
Mechanism of apoptosis regulation by Bcl-2 family proteins 
Apoptosis can be triggered by an insult to a cell. Upon such stimuli, the cell can 
be programmed to die. Bcl-2 family proteins have been shown to promote or inhibit 
apoptosis. Multitude of studies have shown that the Bcl-2 family proteins regulate 
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apoptosis through their ability to regulate the intrinsic apoptotic pathway, also called 
mitochondrial apoptotic pathway, by regulating membrane permeabilization of the 
mitochondria
75
.  
The anti-apoptotic bcl-2 family proteins are found majorly bound to 
mitochondria, endoplasmic reticulum as well as nuclear membranes
75-78
. The pro-
apoptotic proteins on the other hand are found primarily in the cytoplasm or bound to the 
cytoskeleton
61
. Following death signal, pro-apoptotic proteins such as Bax and Bak not 
only translocate to the mitochondria but they also undergo conformational changes that 
enable them to be inserted into the mitochondrial membrane
79, 80
. For example, Bax has 
been shown to insert itself into the outer mitochondrial membrane using its c-terminal 
membrane anchor
81
. This step forms pores on the mitochondria that result in release of 
apoptogenic molecules such as cytochrome c as well as SMAC eventually resulting 
caspase activation as described above
82
. The anti-apoptotic proteins on the other hand 
protect permeabilization of the mitochondrial membrane by binding and antagonizing the 
pro-apoptotic proteins.  
The BH3 only proteins also induce apoptosis through their interaction with Bcl-2 
family proteins. Furthermore, studies have shown that some BH3 only proteins, such as 
Bim or Bid, can interact with Bax and synergize at increasing cell-free permeabilization 
of membrane, which suggest that  some BH3 induce apoptosis not only by interacting 
with anti-apoptotic proteins but also by interacting with pro-apoptotic proteins.  
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IAP family proteins 
IAPs are another family of protein that is known to inhibit apoptosis. IAPs were 
first discovered by Lois Miller and her colleagues in baculovirus 
83, 84
. They were shown 
to inhibit cell death following viral infection. 
Expression of human IAPs 
Eight human IAPs have been identified in human cells and these are NAIAP, c-
IAP1, c-IAP2, XIAP, survivin, Livin, bruce and ILP
85-89
.  The expression of many IAPs 
but that of survivin has been detected in many normal adult tissue
61
.  Overexpression of 
IAP family proteins (XIAP, c-IAP1 and c-IAP2 or survivin) has been shown to inhibit 
apoptosis induced by a variety of stimuli that include withdrawal of growth factors, 
apoptosis-inducing ligand such as Fas as well as drugs such as staurosporin and etoposide 
86, 87, 90, 91
. 
Mechanism of apoptosis inhibition by IAP family proteins 
Several studies investigated the mechanism by which IAPs inhibit apoptosis. 
Many studies show that XIAP, c-IAP1 and c-IAP2 and survivin inhibit directly
92-94
 the 
activities of caspases 3, 7 and 9 but not 1,6,8,or 10. While IAPs are capable of binding to 
pro-caspase 9 in vitro and inhibits activation of caspase 9 by cytochrome c
94
 they were 
shown to bind only to active caspase 3 and 7 
92, 93, 95
. Co-expression of c-IAP1 and c-
IAP2 or survivin with caspase 3, 7, 9 were shown to reduce the ability of caspases to 
induce apoptosis.  
IAPs contain BIR (baculoviral IAP repeat) domains, and depending on the IAP 
protein, they may contain additional domains such as RING or caspase recruiting domain 
(CARD) IAPs contains one to three copies of BIR domain, which is a ~70 residue zinc 
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binding domain. The BIR domain is considered the defining structural characteristics of 
IAP and all members of IAPs contain at least one BIR domain
96-99
. The BIR domain is 
essential for the anti-apoptotic function of IAP proteins
92, 93, 100, 101
 
Some IAPs (XIAP, ILP-2, c-IAP1 and c-IAP2 as well as livin) also contain a 
RING domain, which is another zinc binding motif. Studies have shown that the RING 
domain of IAPs functions as a ubiquitin ligase that leads the auto-degradation as well as 
the degradation of other target proteins.  
 
BIRs function to inhibit apoptosis majorly by mediating protein-protein 
interactions. In IAPs that contain more than one BIR, the second and third BIR domains 
have been shown to bind caspases and regulators of apoptosis
61
 but BIR-1 has been 
shown to interact with signaling intermediates. Overexpressed XIAP BIR1 interacts with 
TGF-B activating kinase 1 (TAK-1) associating subunit 1(TAB1) which then activate 
BIR1 BIR2 BIR3 CARD RING UBC
BRUCE
Survivin
pIAP
cIAP1
cIAP2
XIAP
NIAP
cIAP1
cIAP2
cIAP1
cIAP2
XIAP
pIAP
BRUCE
 
Figure 4. Structure of IAPs. IAPs contain the BIR domain, which is the 
defining structure for this family of proteins. Survivin, which is the smallest 
IAP family protein and BRUCE contain only one BIR domain, where as pIAP 
contain 2 BIR domains and cIAP1, cIAP2, XIAP and NIAP contain three BIR 
domains. cIAP1 and cIAP2 contain caspase recruiting domain (CARD) and 
RING domain in their structure. BRUCE also contains the ubiquitin 
conjugating domain. 
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MAPK signaling
102
. Although survivin harbors only one BIR domain, it has been shown 
to interact with Aurora B through its BIR domain
103
. In addition,  BIR1 domain has been 
shown to interact with other IAP, Eg. XIAP BRI1 interacts with survivin upon apoptosis 
stimuli
61
.  
IAPs and apoptosis 
All IAPs were initially believed to inhibit apoptosis. This observation came from 
studies that overexpression of IAPs, i.e survivin, c-IAP1 and c-IAP2 as well as XIAP 
inhibits caspase 3, 7 and 9. Later, however, it was shown that only XIAP was capable of 
inhibiting caspases 3, 7, and 9
61
. XIAP was shown to bind and inhibit the activation of 
caspases
61
. The BIR3 domain of XIAP binds to caspase 9 and the BIR-2 domain binds to 
caspase 3 and 7
104
. 
Survivin 
Survivin is a member of the IAP family of proteins with dual function in 
apoptosis and cell proliferation
105
. What makes survivin unique is its over-expression in 
most tumors with very little expression in normal cells
90, 106
. Indeed studies have found 
high levels of survivin protein in fetal tissue but almost undetectable in most adult 
tissue
90
. 
The survivin gene is located on the 17q25 chromosome in humans
91
. It undergoes 
alternative splicing and it gives rise to five transcripts. The wild-type survivin is derived 
from exons 1-4 and has 142 amino acids. The other isoform of survivin, 2B, harbors an 
additional segment in its exon 2. The third isoform, survivin ∆EX3, has 137 amino acids 
because of removal of exon 3
107
. Survivin 2 alpha is another transcript that contains exon 
1 and exon 2 and some regions of intron-2 which resulted in acquisition of new a stop 
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codon and a shorter survivin that has only 74 amino acid
108
. Also another transcript 
which is termed as survivin 3B is encoded by exons one to three and a new DNA 
sequence from intron 3 of survivin resulting in a protein with 113 amino acids
109
. 
Although different studies investigated the localization and function of the different 
isoforms of survivin, the wild-type survivin is the most studied isoform of survivin.  
Structure of survivin 
Survivin is the smallest of all human IAPs and contains only one BIR domain and 
an extended C-terminal alpha helix
61
. X-ray crystallography of survivin show that it 
forms a stable homodimer in solution
110, 111
. 
Expression of survivin in cancer and regulation of its expression 
Survivin is differentially expressed in cancer
112
, and except for few normal cells, 
i.e thymocytes, CD34
+
 stem cells as well as basal colonic epithelial cells, it is 
undetectable in most terminally differentiated adult tissue 
61
. This differential expression 
has also been confirmed by the result from a genome wide search that show survivin as 
the fourth most expressed transcriptom in cancer
106
. High expression of survivin in 
cancer has been reported in tumors of colon, breast, lung, pancreas, esophagus, stomach, 
liver, ovary, melanoma, neuroblastoma and other types of cancer
61
. 
How the expression of survivin is upregulated in cancer is not clearly understood 
but some studies shed light about the molecular mechanism. For example, while survivin 
exon1 is highly methylated in normal ovarian epithelium, in most ovarian cancer, it is 
found unmethylated and transcriptionaly active
61
. Also gain of 17q25 in neuroblastoma
61
, 
negative regulation of survivin
61
 and loss of wild-type p53 in many human tumors 
suggest possible mechanism by which survivin could be upregulated in cancer. 
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Several studies show the correlation between increased tumor survivin expression 
and unfavorable patient prognosis or decreased overall survival. High levels of survivin 
have been correlated with decreased patient survival in lung , gastric, colorectal, breast 
cancers and neuroblastoma
61
. Also, increased survivin expression is associated with 
increased risk of recurrence and metastasis in laryngeal carcinoma as well as 
osteosarcoma patients
61
. In addition to this, survivin could be a predictive marker to 
chemotherapy and radiotherapy resistance
61
   
Regulation of survivin expression 
Survivin is expressed constitutively in cancer with peak expression at the G2/M 
phase of the cell cycle
61
. The survivin promoter harbors cell cycle dependent elements 
(CDE) and cell cycle gene homologue region (CHR) and is believed to play role in the 
cell cycle regulated expression of survivin
61
. 
The transcription of survivin in cancer is believed to be regulated by several 
transcription factors. For example, studies have shown that the signal transducer and 
activator of transcription (STAT-3)
61
 and E2F
61
 positively regulate survivin expression. 
Over expression of dominant negative STAT-3 or pharmacological inhibition of STAT-3 
has been shown to reduce the transcription of survivin
61
. Similarly, the tumor suppressers 
p53
61
 and APC
61
 negatively regulate survivin expression. 
Beside the transcriptional regulation of survivin, post-translational modifications 
of survivin have been shown to regulate the expression of survivin. Survivin has been 
shown to undergo phosphorylation at Thr-34, which is believed to inhibit survivin 
degradation by the proteasome. The only known kinase to phosphorylate Thr-34 is 
cyclin-dependent kinase 1 (CDK1)
61
. This kinase is active at the G2/M phase of the cell 
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cycle, therefore it is possible to speculate that beside the CDE/CHR role, this 
phosphorylation could be responsible for the higher survivin expression levels at G2/M. 
Indeed, co-immunoprecipitation of survivin with CDK1 from cells that were 
synchronized at G2/M has been demonstrated and over expression of kinase dead CDK1 
resulted in lower phosphorylation of survivin at this amino acid residue.  
Role of survivin in cell cycle and apoptosis 
The role of survivin in the regulation of cell cycle and apoptosis has been under 
intense scrutiny. With regards to cell cycle regulation, survivin as a member of the 
chromosomal passenger complex (CPC) is involved in the regulation of cell division 
through its association with INCENP and Aurora B on the centromere
61
. RNAi mediated 
depletion of survivin leads to impaired localization of the CPC at the centromere and 
mitotic spindle which resulted in interference with mitotic progression. Also, other 
studies have shown that siRNA mediated depletion of survivin resulted in the absence of 
aurora B and INCENP from centromere, misaligned chromosomes and in multi-nucleated 
cells
61
. In addition, in vitro studies showed that the G2M kinase Aurora B phosphorylates 
survivin at Thr-117.  
Role of survivin in apoptosis 
The evidence for the ability of survivin to inhibit apoptosis comes from different 
studies that were done both in-vitro as well as in-vivo. Several studies have shown that 
survivin is able to protect cells from extrinsic and intrinsic mediators of apoptosis 
including withdrawal of interleukins, stimulation with Fas ligand, over expression of pro-
apoptotic proteins such as p53, Bax, caspase 3 and 8
90, 94, 107, 113-116
. Additional evidence 
for survivin’s role in apoptosis comes from the observation that using survivin dominant 
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negative mutants, ribozymes, anti-sense as well as siRNA induces spontaneous apoptosis 
in vivo
117-124
. Also, transgenic mice that express survivin at the basal layer of the 
epidermis using cytokeratin-14 promoter block apoptosis induced by UV irradiation
125
. 
Although the above studies convincingly demonstrate the anti-apoptotic role of 
survivin, the exact molecular mechanism by which survivin interfere in apoptosis is not 
known. Different studies have shown association of survivin with initiator and effector 
caspases 
94, 126, 127
 however whether survivin inhibit caspase activation is uncertain
128-130
 .  
For example, while Tamm et al found that cellular survivin inhibits caspases, chemically 
synthesized survivin fails to do so. However, from x-ray crystallography structural 
studies, it is now clear that except for XIAP, all other IAPs lack the structure features to 
inhibit caspases
61
. 
The following are literature gaps filled by the work of this thesis concerning the 
mechanism by which cancer cells maintain high levels of the survivin protein and the 
contribution of the Ras and Ral GTPases in this process.  
The high levels of survivin in cancer cells and the lack of expression in most 
normal tissues strongly suggest that some of the genetic alterations of cancer cells result 
in up regulation of survivin.  While activation of STAT3, NFkB, Notch and Wnt as well 
as inactivation of the tumor suppressors p53 and Rb all have been shown to increase 
survivin expression, little is known about the regulation of survivin by the GTPases Ras 
and Ral. In this thesis, we investigated whether the expression of mutant K-Ras is 
required for the maintenance of the high levels of survivin in human tumors.  We also 
determine whether K-Ras depletion attenuates both basal and drug-induced survivin 
levels. We also determined the mechanism by which K-Ras depletion decreases survivin 
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levels by investigating the phosphorylation, ubiquitination and proteasomal degradation 
of survivin. Furthermore, we investigated whether depletion of RalA, RalB, Raf-1, Akt1 
or Akt2 decreases survivin levels.  Finally, we evaluated whether the ability of mutant K-
Ras to induce anchorage-independent growth, invasion and survival is compromised by 
depletion of survivin. 
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Chapter 2 
 
K-Ras requirement for survivin stability and survivin contribution to K-Ras driven 
malignant transformation 
 
Note to Readers 
 Portion of these results have been previously published (Awet Tecleab and Said 
Sebti, Cell Cycle 12:3, 522–532; February 1, 2013) and are utilized with permission of 
the publisher. 
 
Abstract 
Mutant K-Ras and high levels of survivin contribute to oncogenesis but little is 
known about K-Ras requirement for survivin maintenance and survivin contribution to 
K-Ras-driven malignant transformation.  Here we demonstrate that K-Ras depletion 
significantly decreases survivin levels in human cancer cells that harbor mutant but not 
wild K-Ras.  K-Ras depletion also suppresses the ability of drugs such as paclitaxel and 
VP16 to induce survivin levels. The mechanism by which K-Ras depletion decreases 
survivin levels is through ubiquitination and proteasomal degradation of survivin, and is 
independent of survivin-Thr-34 phosphorylation.  Furthermore, the ability of mutant K-
Ras to induce anchorage-independent growth, invasion and survival is compromised by 
depletion of survivin.  These studies suggest that mutant K-Ras contributes to the 
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maintenance of the high survivin levels by regulating its stability, and that the ability of 
mutant K-Ras to induce malignant transformation is at least in part dependent on  
survivin. 
Keywords: Apoptosis / Cancer / K-Ras / Protein degradation / Survivin 
Introduction 
One of the critical requirements for normal cells to become cancerous is to 
acquire the ability to evade programmed cell death (apoptosis) even when challenged 
with unfavorable conditions such as cytotoxic agent or radiation exposure 
1
.  The Bcl-2 
family as well as and the inhibitors of apoptosis (IAP) family of proteins play essential 
roles in the regulation of apoptosis. While the Bcl-2 family proteins monitor cell death by 
controlling the release of cytochrome c from mitochondria, the IAP family proteins 
prevent cell death by inhibiting the activation of caspases
2, 3
. Survivin is one of the 
members of the IAP family known to play critical roles in promoting cell cycle 
progression 
4
 and in preventing apoptosis
5
. During cell cycle progression, survivin 
mediates proper loading of the chromosomal passenger complex, chromosomal 
segregation, spindle formation and microtubule stabilization
6, 7
. The role of survivin as an 
anti-apoptotic protein has also been investigated thoroughly, and depending on the cell 
type, survivin inhibits either spontaneous apoptosis or drug-induced apoptosis
8
.  Despite 
its prominent role in apoptosis, the mechanism by which survivin blocks apoptosis 
remains elusive.  Some studies suggested that survivin protects against apoptosis through 
direct binding to caspases 
5
 whereas other studies demonstrated that XIAP (another IAP 
member) but not survivin directly binds caspases
9
. More recent studies demonstrated that 
survivin binds and cooperates with XIAP to efficiently block caspase activation
10
. 
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Unlike other IAPs, little to no survivin is expressed in normal cells. In contrast, 
virtually all cancer cells maintain very high levels of survivin protein
11
. The fact that 
survivin protein levels are much higher in cancer cells as compared to normal cells 
indicates that some oncogene may be responsible for the maintenance of these high 
levels. In deed, the induction of survivin expression in cancer cells has been attributed to 
some mutated or deregulated oncogenes/ proto-oncogenes in cancer. For example, 
aberrant activation of STAT3, NFkB, Notch and Wnt as well as inactivation of the tumor 
suppressors p53 and Rb all have been shown to increase survivin expression by 
regulating its transcription 
12
.  
Mutations in the small GTPase Ras and high levels of the survivin protein are 
prevalent in human tumors but the role of mutant Ras in regulating survivin protein levels 
has not been thoroughly studied, and the very few studies reported, investigated mainly 
the role of ectopically expressed H-Ras but not K-Ras, the most frequently mutated 
isoform of Ras in human cancer.  Previous studies showed that, ectopic over expression 
of c-H-Ras in Rat cells as well as in human keratinocytes induces survivin expression 
13, 
14
.  Furthermore, Fukuad et al. showed that exogenous H-Ras is required for interleukin 
induced survivin in Baf-3 cells 
15
.  However, other studies showed that mutant H-Ras is 
not able to increase survivin
16
.  Furthermore, the requirements of endogenous Ras for the 
maintenance of the high levels of survivin in cancer cells have not been investigated.  
Finally, several studies have documented both in vitro and in vivo the importance of 
survivin to malignant transformation 
17, 18
 but little is known about the contributions of 
survivin to mutant K-Ras-driven transformation.   
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In this thesis, we demonstrated that depletion of K-Ras decreases survivin levels 
in human cancer cells that harbor mutant K-Ras but not wild type Ras, and that this 
decrease in the survivin protein levels is due to proteasome degradation, suggesting that 
mutant K-Ras regulates survivin stability. Furthermore, we also demonstrated that 
depletion of survivin significantly reduces mutant K-Ras-driven anchorage-independent 
growth and invasion suggesting that survivin contributes to K-Ras driven malignant 
transformation.  
Materials and Methods 
Cell culture 
The human tumor cell lines were grown in their respective media: A549 in 
Kaighn's modification medium (F12K) (Gibco Laboratories, Grand Island, NY), Calu-1 
and SKOV-3 in McCoy’s 5a medium modified (Sigma-Aldrich, St.  Louis, MO), H460, 
AsPC-1, Ovcar-5 and BxPC-3 in RPMI, (Invitrogen, Carlsbad, CA), MiaPaCa-2, Panc-1, 
SW1990, and HOP-92 in Dulbecco’s modified minima essential medium (DMEM) 
(Invitrogen). All cells were grown in their respective media containing 10% FBS and 1% 
penicillin streptomycin at 37
o
C in a humidified incubator at 5% CO2. Human Pancreatic 
Nestin Expressing  (HPNE) cells were the kind gift of Dr Channing Der and Dr Paul 
Campbell (University of North Carolina) and were maintained in media containing 3:1 
mixture of DMEM and M3F base media (INCELL, San Antonio, TX).  NIH-3T3 cells 
that stably express mutant K-Ras and C7 cells that stably express mutant K-Ras were 
grown as described by us 
19, 20
 respectively.  
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siRNAs and antibodies 
Non-targeting (NT) and K-Ras siRNA were purchased from Dharmacon, 
Lafayette, CO and Ambion, Grand Island, NY, respectively.  Survivin antibodies were 
purchased from Novus biologicals, Littleton, CO (used for immunoprecipitation), and 
Abcam, Cambridge, MA (used for western blotting). Bax, MCL-1, Bad and ubiquitin 
antibodies were purchased from SantaCruz Biotechnology Santa Cruz, CA.  Cleaved 
PARP antibody was purchased from Cell Signaling, (Danvers, MA). β-actin, vinculin, α-
tubulin and GAPDH antibodies were purchased from Sigma. K-Ras (OP-24), Bcl-2 and 
Bcl-XL antibodies were purchased from Calbiochem, Billerica, MA. XIAP antibody was 
purchased from BD Biosciences, San Jose, CA. Peroxidase conjugated Goat anti-mouse 
IgG, Rabbit anti-Goat IgG, Mouse anti-Rabbit IgG antibodies were purchased from 
Jackson immunoResearch Laboratories, West Grove, PA. TrueBlot mouse secondary was 
purchased from e-Bioscience San Diego, CA.  
DNA constructs and site directed mutagenesis 
Survivin T34 mutants were generated using QuickChange II XL site directed 
mutagenesis kit (Agilent Biotechnologies, Santa Clara CA). Survivin ORF plasmid was 
purchased from Origene and used as a template to do site directed mutagenesis according 
to the manufacturer’s recommendation. Briefly, primers were designed using an online 
primer designing tool from Agilient Biotechnology, www.agilent.com/genomics.  
The following primers were purchased from Integrated DNA Technology (IDT).  
Survivin T34D:  Sense primer: 5’-GGGCTGCGCCTGCGACCCGGAGCGGATG-3’; 
Antisense primer: 5’-CATCCGCTCCGGGTCGCAGGCGCAGCCC-3’.  Survivin 
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T34A :  Sense primer: 5’-GCTGCGCCTGCGCCCCGGAGCGG-3’ ;  Antisense primer:- 
5’-CCGCTCCGGGGCGCAGGCGCAGC-3’. 
PCR conditions:  The following components were added into a PCR tube- 
reaction buffer to 1X, 200ng DNA, 125ng of each sense and antisense primers, 1ul of 
dNTP mix, 3ul of quicksolution and distilled water to a final volume of 50ul and DNA 
polymerase (all reagents from Agilent Biotechnologies). PCR cycle conditions: 95
o
C-
2min, 95
o
C-1min, 60
o
C-50 sec, 68
o
C 14min, 68
o
C 7min, repeat 18 times then end. 
Following temperature cycling, the reaction tubes were placed on ice for 2min, followed 
by the addition of 2 μL DPN1 restriction enzyme to each sample. This reaction was 
allowed to go for at least 4 hr at 37
o
C.  After generation of the plasmid, bacteria (XL10- 
Gold Ultra competent Cells) were transformed per the manufacturer’s instructions.  After 
overnight incubation, 10 colonies were picked for each sample. DNA was purified to 
determine mutation status.  
Cloning of myc-tagged CA-K-Ras12V 
We used our previously described K-Ras-Q12V pBABE expression construct 
21
 
as template to clone into myc-tagged pCMV-Tag3B vector. The following primers were 
used to shuttle the construct: 
Forward primer: 5’-CGC GGA TCC AAG CTT ATG ACT GAA TAT AAA CTT GTG 
GTA-3’,  
Reverse primer: 5’-TGC TCT AGA CTC GAG TTA CAT AAT TAC ACA CTT TGT 
CTT-3’ 
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siRNA transfection 
Cells were transfected with siRNA using Lipofectamin RNAiMAX transfection 
reagent (Invitrogen) according to the manufacturer’s instructions. Briefly, cells were 
plated overnight to reach ~40-50% confluence at the time of transfection. Lipofecatmine 
RNAiMAX and Optimum were mixed in one tube and a mixture of siRNA and Optimum 
was prepared in another tube, and the content of the two tubes were mixed.  The mixture 
was incubated for 20 min at room temperature, after which the siRNA-RNAiMax mixture 
was added to cells drop-wise. After 24 hrs of transfection, appropriate media that contain 
10% serum only was added until the desired time of transfection.  
DNA transfection and generation of stable cell lines 
Cells were plated overnight to reach 70-80% confluence and were then 
transfected with DNA using Lipofectamine 2,000 transfection reagent according to the 
manufacturer’s instructions.  Briefly, Lipofectamine 2,000 reagent (1.5μl/μg of DNA) 
was diluted in OPTI-MEM medium (Invitrogen) and allowed to equilibrate for 5 min at 
room temperature. 2μg of DNA (vector or Myc-DDK-survivin construct), (Origene, 
Rockville, MD) was diluted in OPTI-MEM in a separate tube. The contents of the two 
tubes were mixed and allowed to complex for 20 min at room temperature, and added 
drop wise to cells that contain 10% FBS but no 1% PS. The cells were transfected for 6 
hrs before changing the medium to medium containing 10% FBS only and incubated for 
an additional 18 hrs. The medium was then replaced with complete growth medium 
containing 1.2mg/mL of G418 (Fisher Scientific, Pittsburgh, PA). The cells were kept in 
selection medium for 2 weeks after which the resistant cells were pooled and grown for 
further experiments.  
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Western blotting 
Cells were rinsed with ice cold PBS twice and lysed on the plate in lysis buffer 
containing 20mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-
100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerolphosphate, 1 mM sodium 
orthovanadate, 1ug/mL leupeptin, and 1 mM PMSF. The lysate was collected by scraping 
and centrifuging at 13000g for 13 min to remove the debris. The protein content was 
measured using Bradford protein assay. Samples were resolved using 12.5% SDS-PAGE 
and transferred to PVDF membranes (Millipore, Billerica, MA). The membranes were 
blocked with 5% milk in Tris-Buffered Saline and Tween 20 (TBST) and then probed 
with the desired antibodies. The enhanced chemiluminescence blotting system 
(PerkinElmer Inc, Waltham, MA) was used for antibody reaction. 
Immunoprecipitation 
Cells were rinsed with ice cold PBS twice and lysed on the plate in NP-40 lysis 
buffer containing 20 mM Tris pH 7.5, 0.05% Igepal, 250mM NaCl, 3mM EGTA, 3mM 
EDTA, 2mM NaVO4, 2mM PMSF  and 7.4mg/ml PNPP, 0.5uM bortezomib, Ub-
aldehyde 4μM, 20mM n-ethylmaleimide. After collecting the lysate, the lysate was 
sonicated (4 pulses), using Branson Sonifier, VWR Scientific, at output level 3, duty 
cycle (%) 30. After clearing the debris by centrifuging at 13,000g for 13minutes, the 
protein amount was measured. 600-1000μg of protein was incubated with 30μl of 50/50 
mix of protein A/ protein G agarose beads (Millipore) and 2μg/ml of survivin antibody 
(Novus) at 4
o
C overnight on an orbital shaker. After overnight incubation, the sample 
was centrifuged for 5 second to collect the beads. The supernatant was discarded and the 
beads were washed two times with 500μl lysis buffer. The agarose beads were re-
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suspended in 30ul of sample buffer. The agarose beads were boiled for 5minutes to 
dissociate the immunocomplex from the beads. The beads were collected by centrifuging 
and the proteins in the supernatant were run on a 12.5% SDS-PAGE.  
In-vivo ubiquitination assay 
Panc-1 cells were first transfected with siRNA for 48hr. The cells were then 
treated with 0.5uM of bortezomib (Velcade) for 30min. The cells were then lysed with 
NP-40 lysis buffer. Survivin was immunoprecipitated as described above and 
ubiquitinated survivin was detected using ubiquitin antibody from SantaCruz 
Biotechnology and TrueBlot mouse secondary (eBioscience).  
Caspase activation assay 
Caspase-3 activity was measured in cell lysates using a fluorogenic substrate. The 
assay measures the cleavage of AMC groups from a Caspase-3 specific substrate (Ac-
DEVD-AMC) (Biomol Research Labs, Inc., plymouth Meeting, PA).  Liberated AMC 
groups were quantified on fluorometer at excitation max.: 365–380 nm and emission 
max.: 430–460 nm. Briefly, cells were lysed in a protease inhibitor free lysis buffer 
(50mM Tris, pH 8, 5mM EDTA, 150mM NaCl, 0.5% NP-40). The lysate was collected 
by scraping. After clearing the lysate by centrifugation, protein was measured. 20 μg of 
protein and 20 μM caspase-3 substrate were added into 50mM Tris, pH 7.5 reaction 
buffer in triplicate in a 96-well plate. The reactions were incubated for 1h at 37
o
C and the 
plate was read by a fluorometer, WALLAC Victor 1420 Multilabel counter with 355nm 
excitation and 460nm emission filters (Perkin Elmer Life Sciences, Turku, Finland).  
Assay for the chymotrypsin-like activity (CT-L) of the proteasome 
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The (CT-L of the proteasome was measured using fluorogenic peptide substrate 
as described elsewhere 
20. Briefly, 20μg of cell lysate protein was incubated with 20μM 
of Suc-Leu-Leu-Val-AMC substrate for CT-L activity in 100μL of assay buffer (50mM 
Tris-HCl, pH 7.6) for 1hr at 37oC. After incubation, production of 7-hydrolyzed 7-
amido-4-methyl-coumarin (AMC) groups were measured using WALLAC Victor 1420 
Multilabel counter with 355nm excitation and 460nm emission filters (Perkin Elmer Life 
Sciences, Turku, Finland). 
Soft agar colony formation assay 
After 48 hrs of siRNA treatment, the cells were trypsinized, counted and seeded at 
a cell density of 2,000/well in triplicate in 12-well culture plates in 0.3% agar over a 
0.6% bottom agar layer as previously described
21
. Cultures were incubated until colonies 
formed (approximately 2-3 weeks). Plates were scanned after overnight incubation with 1 
mg/ml MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 
Calbiochem), in cell growth medium. The colony numbers were visually determined and 
quantified.  
Cell invasion assay 
Analysis of cell invasion was performed using artificial extracellular matrix 
(Matrigel, 8uM pore size, BD Biosciences, Bedford, MA) according to the 
manufacturer’s instructions. Briefly, the inserts were rehydrated by adding warm serum-
free medium for 2 hrs at 37
o
C, 5% CO2 atmosphere. The medium was then removed from 
the inserts, and 750ul of medium containing FBS was added to each well of the plate and 
the inserts were placed on top of the medium. The transfected A549, Panc-1, and H460 
(40,000 cells in 500ul of serum free-media) and HPNE cells (20,000) were added into the 
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inserts. The cells were incubated for 48 hrs at 37
o
C. Cell invasion was determined by 
staining the bottom parts of the insert with crystal violet (0.5% crystal violet in 25% 
methanol). The porous membrane was removed and placed on the slide. The number of 
cells that invaded were counted in three high-power microscope (40X) fields and 
averaged as the mean number of invaded cells per field for each membrane.  
Cell lines 
The human cancer cell lines Calu-1, Panc-1, Hop-92 and Tov-21G, A549, SKOV-
3, ASPC-1, BxPC-3, and SW1990, H460 and Ovcar-5 were all obtained from ATCC but 
none of the cell lines have been authenticated. 
Results 
Depletion of K-Ras decreases survivin levels in human cancer cells that harbor mutant, 
but not wild type K-Ras. 
Both mutant K-Ras and high levels of survivin contribute to malignant 
transformation and are associated with poor cancer patient prognosis.  However, whether 
mutant K-Ras is required for the maintenance of high survivin levels is not known.  To 
address this important question we first depleted K-Ras from several human cancer cell 
lines that either harbor mutant K-Ras or wild type Ras, and determined the effect of this 
depletion on the levels of survivin.  Human cancer cell lines from various origins 
including pancreatic (Panc-1, MiaPaca-2, SW1990, ASPC-1, BXPC-3), lung (A-549, 
Calu-1, H460, HOP-92) and Ovarian (OVCAR5, SKOV-3), were transfected with non-
targeting (NT) or K-Ras siRNA and processed for western blotting as described under 
Materials and Methods.  Figure 5A show that siRNA to K-Ras depleted K-Ras and that 
this resulted in a significant decrease in the protein levels of survivin in cell lines that  
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harbor mutant K-Ras (Panc-1, Calu-1, H460, AsPC-1, MiaPaca-2, SW1990, A-549 and 
OVCAR5) but not in those cancer cell lines that express only wild type Ras (BXPC3, 
SKOV-3 and HOP-92).   
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Figure 5. Depletion of K-Ras decreases survivin levels in human cancer 
cells that harbor mutant K-Ras. A. Human cancer cell lines that harbor mutant 
K-Ras (Panc-1, AsPC-1, A549, H460, MiaPaCa-2, Calu-1,SW1990) or wild type 
Ras (BXPC3, HOP-92, Skov-3) were transfected either with non-targeting 
siRNA (NT) or K-Ras siRNA and the cells were processed for western blot 
analysis as described in Materials and Methods.  B. Panc-1 cells were 
transfected with siRNA#2 that targets different regions of K-Ras mRNA and 
processed for western blot analysis as described above. C. Depletion of K-Ras 
reduces both exogenous and endogenous survivin. Panc-1 cells that stably 
express either vector or MYC-DDK-Survivin were transfected with siRNA and 
the cells were processed for western blot analysis as above.  D. Panc-1 cells 
were treated with siRNA for 36 hrs followed by VP-16 treatment for 24 hrs. Cells 
were processed for western blot analysis as above.  Data are representative of 
at least two independent experiments. 
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Next we used another K-Ras siRNA that target a different region of K-Ras 
mRNA to confirm the results. Figures 5A and 5B show that depletion of K-Ras by two 
distinct K-Ras siRNAs reduces survivin levels.  Whether depleting K-Ras also reduces 
the levels of ectopically expressed survivin was next investigated. To this end, cells were 
stably transfected with Myc-DDK-tagged survivin and survivin protein levels were 
determined following siRNA to NT or K-Ras transfection as described under Materials 
and Methods. Figure 5C shows that depletion of K-Ras reduces the levels of endogenous 
as well as exogenous survivin. The fact that depletion of K-Ras reduces the levels of 
exogenous survivin, the expression of which was driven by a foreign promoter, suggests 
that K-Ras may affect survivin levels by regulating its stability (see more below).  
Depletion of K-Ras reduces the ability of VP16 to increase survivin levels. 
Previous studies have shown that treatment with chemotherapeutic drugs such as 
paclitaxel and VP16 results in survivin induction, and that this is an intrinsic mechanism 
by which tumor cells develop resistance to chemotherapy. Since we found depletion of 
K-Ras to decrease basal survivin protein levels, we reasoned that depletion of K-Ras may 
also prevent induction of survivin by anticancer drugs in cancer cells that harbor mutant 
K-Ras. Therefore, we next investigated whether the VP16- and paclitaxel mediated 
increase in survivin levels requires mutant K-Ras.  To this end, Panc-1 cells were 
transfected with siRNA to K-Ras or NT siRNA and treated with vehicle, VP16 or 
paclitaxel and processed for western blotting as described under Materials and Methods.  
Figures 5D and 5E show that in the absence of siRNA to K-Ras VP16 and paclitaxel 
treatment of Panc-1 cells resulted in a robust increase in survivin levels.  In contrast, in 
Panc-1 cells where K-Ras was depleted, the ability of VP16 and paclitaxel to induce 
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survivin was significantly compromised (Figures 5D and 5E). These results suggest that 
K-Ras expression is required for the ability of VP16 and paclitaxel to increase survivin 
protein levels, further confirming the role of mutant K-Ras in maintaining high levels of 
survivin.  
Ectopic expression of mutant K-Ras is not sufficient to induce survivin 
Figure 5 demonstrated that depletion of K-Ras resulted in decreased levels of 
endogenous and exogenous survivin as well as drug-induced survivin.  Next we 
determined if ectopic expression of mutant, constitutive active K-Ras (CA-K-Ras), 
increases survivin levels.  
 
Human embryonic kidney HEK293 cells that ectopically express CA-K-Ras and 
their parental counterpart that were transfected with an empty vector construct were used.  
Figure 6A shows that forced expression of CA-K-Ras did not affect the protein levels of 
survivin.  Similar results were also obtained with NIH-3T3 cells as well as two primary 
pancreatic ductal cell lines C7 and HPNE that stably express either CA-K-Ras or empty 
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Figure 6. Ectopic expression of CA-K-Ras is not sufficient to induce 
survivin. HEK293 (A), NIH3T3 (B), HPNE (C) and C7 (D) cells that 
stably express CA-K-Ras or vector were plated and grown for 48 hrs and 
western blot analysis was performed to determine the survivin levels.  
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vector (Figures 6B, 6C and 6D), suggesting that K-Ras is not sufficient to drive the 
expression of survivin.  Taken together, the results from Figures 5 and 6 suggest that 
mutant K-Ras is required but not sufficient for the maintenance of the high survivin 
levels in human cancer cells.  
Depletion of K-Ras decreases the stability of survivin by promoting its ubiquitination 
and proteasome degradation. 
Previous studies have shown that survivin protein undergoes proteasomal 
degradation. To determine if depletion of K-Ras leads to decreased survivin protein 
levels by inducing its proteasomal degradation, we used the proteasome inhibitor 
bortezomib. First, we demonstrated that treatment of Panc-1 cells with bortezomib 
resulted in the accumulation of survivin in a time-dependent manner starting as early as 1 
hr and reaching a maximum at 4 hrs (Figure 7A). Next, whether bortezomib can rescue 
from the K-Ras depletion-mediated decrease of survivin levels was investigated.  To this 
end, Panc-1 cells that stably express Myc-DDKtagged survivin were transfected with 
either NT or K-Ras siRNA for 48 hrs prior to incubation with bortezomib for 1 hr and 
processed the cells for western blotting as described under Materials and Methods.  
Figure 7B shows that vector cells express only endogenous survivin whereas Myc-
survivin transfected cells express both endogenous and exogenous survivin (compare 
lanes 1 and 2).  In the absence of bortezomib, depleting K-Ras resulted in a significant 
decrease of both endogenous and exogenous survivin levels (compare lanes 3 and 5).  In 
contrast, treatment of cells with bortezomib inhibited the ability of K-Ras siRNA to 
decrease the levels of both endogenous and ectopically expressed survivin (compare 
lanes 4 and 6 to lanes 3 and 5).  Figure 7B also shows that bortezomib inhibited the CT-L 
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activity of the proteasome by 83% and 88% in Panc-1 cells transfected with NT siRNA 
and K-Ras siRNA, respectively. 
We next determined whether K-Ras siRNA induces the degradation of survivin 
by increasing its ubiquitination.  To this end, survivin was immunoprecipitated from cells 
that were transfected with siRNA to NT or K-Ras for 48 hrs followed by bortezomib 
treatment as described under Materials and Methods. Figure 7C shows more 
ubiquitinated survivin in the siRNA to K-Ras transfected cells.  Thus, the results from 
Figures 7B and 7C suggest that K-Ras depletion leads to ubiquitination and proteasome-
mediated degradation of survivin.  
Phosphorylation of survivin at T34 has been shown to increase the stability of 
survivin
22, 23
. One possible mechanism by which depletion of K-Ras could decrease the 
stability of survivin is by inhibiting the phosphorylation of survivin at T34. We therefore 
reasoned that the phospho mimic T34D survivin mutant should be resistant to K-Ras 
depletion.  To this end, we generated the T34D survivin mutant as well as the non-
phosphorylatable T34A mutant.  Panc-1 cells that stably express either wild type (WT), 
T34D mutant or T34A mutant were transfected with siRNA to NT or K-Ras for 48 hrs 
and the expression of survivin was followed by western blotting as described under 
Materials and Methods.  
Figure 7D shows that depletion of K-Ras reduces the expression of WT survivin 
as well as T34A and T34D survivin mutants suggesting that the ability of K-Ras siRNA 
to decrease survivin protein levels is not dependent on the phosphorylation status of 
survivin at T34.  
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Figure 7. Depletion of K-Ras decreases survivin protein levels in a 
proteasome dependent manner and a survivin-T34 phosphorylation 
independent manner 
A. Panc-1 cells were treated with the indicated dose of bortezomib for 1 hr. The 
media was then replaced with drug-free media and the cells were allowed to grow 
for the indicated length of time and processed for western blotting as described in 
Materials and Methods.  B. Panc-1 cells stably expressing Myc-DDK survivin were 
treated with siRNA to NT or K-Ras, followed by vehicle or bortezomib treatment. 
Cells were then harvested for western blot analysis or CT-L proteasome activity 
assay as described in the Materials and Methods. C. A549 cells were transfected 
with NT or K-Ras (K) siRNA for 48 hrs followed by bortezomib treatment for 30 min. 
Survivin was immunoprecipitated and processed for western blot analysis for either 
ubiquitin or survivin. D.  Panc-1 cells that stably express vector, wt, T34A mutant or 
T34D mutant survivin were transfected with NT or K-Ras siRNA and the cells 
processed for western blotting as described in Materials and Methods. Data are 
representative of at least two independent experiments. 
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Depletion of K-Ras decreases selectively survivin over the anti-apoptotic proteins Bcl-2, 
Bcl-XL and Mcl-1, and does not increase the levels of the pro-apoptotic proteins Bax 
and Bad. 
The ability of cancer cells to survive depends not only on IAP family members 
but also on a balance between anti-apoptotic and pro-apoptotic Bcl-2 family members.  
We therefore determined whether K-Ras depletion selectively affect survivin over other 
proteins that regulate cancer cell survival. To this end, in addition to survivin, we 
evaluated the effects of K-Ras depletion on anti-apoptotic (Bcl-2, Bcl-XL and Mcl-1) and 
pro-apoptotic (Bad and Bax) proteins. Figure 8 (in the following page) shows that siRNA 
to K-Ras decreased the levels of survivin but doesn’t affect the levels of the Bcl-2 family 
proteins in Panc-1 and MiaPaca-2 cells.  
Survivin is required for mutant K-Ras-driven malignant transformation 
Both survivin and mutant K-Ras contribute to malignant transformation, but 
whether survivin is required for K-Ras-driven malignant transformation is not known.  In 
an attempt to address this question, we next determined if depletion of survivin induces 
apoptosis in HNPE cells where malignant transformation was induced by mutant K-Ras. 
Figure 9 shows that depletion of survivin induces apoptosis in HPNE-K-Ras cells as 
measured by caspase 3 activation and PARP cleavage, suggesting that survivin is a 
critical protein that mediates at least in part the anti-apoptotic function of K-Ras. To 
further confirm this result, we used different cell lines that harbor mutant K-Ras and 
determined if depletion of survivin induces apoptosis. Our result shows that depletion of 
survivin induces caspase 3 activation and PARP cleavage in A549 and H460 but not in 
panc-1 cells. 
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In addition to the well studied function of survivin in apoptosis, recent study have also 
demonstrated that survivin contributes to invasion and metastasis and this role is 
independent of its anti-apoptotic activity 
24
.  The ability of cancer cells to grow in an 
anchorage-independent manner is a prerequisite to metastasis.  We therefore determined 
if mutant K-Ras-induced colony formation in soft agar of HPNE pancreatic cells depends 
on survivin.  Figure 10 shows that HPNE cells transfected with vector grew 62 colonies 
in soft agar. Transfection with mutant K-Ras enhanced the ability of HPNE cells to grow 
soft agar colonies by 6.6-fold from 62 (vector cells) to 412 (K-Ras cells) colonies.  Figure 
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Figure 8. Depletion of K-Ras reduces survivin levels but does not affect 
the levels of Bcl-2 family proteins. Panc-1 and MiaPaCa-2 cells were 
transfected with siRNA to K-Ras or NT for 48 hrs and the expression of 
different members of BCL-2 family proteins as well as expression of survivin 
and XIAP were detected by western blot analysis. Data are representative of 
two (MiaPaCa-2) or three (Panc-1) independent experiments.  
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10 shows that depletion of survivin potently inhibited this K-Ras-dependent increase in 
colony formation in soft agar. This suggests that the ability of K-Ras to promote 
anchorage- independent growth partly depends on survivin.  Furthermore, the ability of 
H-460 and Panc-1 cells, both of which harbor mutant K-Ras, to grow soft agar colonies 
was also inhibited by depletion of survivin. 
Panc-1 H460
N
T
S
ur
vi
vi
n
0
500
1000
1500
F
lo
re
s
c
e
n
c
e
 u
n
it
A549
NT       Survivin NT      Survivin NT       Survivin
Actin
Survivin
C. PARP
Actin
Survivin
C. PARP
Actin
Survivin
C. PARP
N
T
S
ur
vi
vi
n
0
200
400
600
800
F
lo
re
s
c
e
n
c
e
 u
n
it
N
T
S
ur
vi
vi
n
0
100
200
300
400
F
lo
re
s
c
e
n
c
e
 u
n
it
N
T
S
ur
vi
vi
n
0
200
400
600
800
1000
F
lo
re
s
c
e
n
c
e
 u
n
it
NT    Survivin
GAPDH
Survivin
C. PARP
HPNE-K-
Ras12D
P=0.02 P=0.005 P=0.54 P=0.02
F
lo
re
s
c
e
n
c
e
 u
n
it
F
lo
re
s
c
e
n
c
e
 u
n
it
F
lo
re
s
c
e
n
c
e
 u
n
it
F
lo
re
s
c
e
n
c
e
 u
n
it
 
Figure 9. Depletion of survivin induce apoptosis in some cells. HPNE-K-Ras, 
A549, Panc-1 and H460 cells were transfected with either control (NT) or survivin 
siRNA for 96 hrs. Top panel: western blot analysis showing knockdown of survivin 
and cleaved PARP and, bottom panel: caspase-3 activity following depletion of 
survivin. Experiment was done in triplicates and error bars show SD deviation 
between the triplicate wells. P value was calculated using the 3 values from the 
triplicates and SD. Data are representative of two independent experiments.  
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While anchorage-independent growth is a pre-requisite for metastasis, another 
close hallmark of metastasis is invasion. We therefore determined if mutant K-Ras-driven 
invasion requires survivin.  Figure 11 shows that mutant K-Ras increased the ability of 
HPNE cells to invade by ~3.7-fold from 18 in vector cells to 67 in K-Ras transformed 
cells. Figure 11 also shows that depletion of survivin inhibited the ability of K-Ras to 
induce invasion. Similarly, in A-549, H-460 and Panc-1 cells, all of which harbor mutant 
K-Ras, depletion of survivin significantly compromised their ability to invade (Figure 
11). 
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Figure 10. Depletion of survivin compromises K-Ras-driven anchorage 
independent growth.  HPNE-Vector, HPNE-K-Ras, Panc-1 and H460 cells were 
transfected with the indicated siRNA for 48 hrs and were plated for soft agar analysis 
as described under Materials and Methods. Experiment was done in triplicates and 
error bars show SD deviation between the triplicates wells. P value was calculated 
using the 3 values from the triplicates and SD. Data are representative of two (H460) 
or three (HPNE and Panc-1) independent experiments.  
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Discussion 
The contributions of mutant K-Ras to several hallmarks of cancer including 
deregulation of anchorage-dependent and –independent cell growth, invasion, metastasis 
and apoptosis evasion have been well documented.  In contrast, until recently, survivin 
has only been well documented in preventing apoptosis and promoting mitosis.  Recent 
studies have demonstrated, as is the case for K-Ras, that survivin is also involved in other 
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Figure 11. Depletion of survivin compromises K-Ras-driven invasion. HPNE-
Vector, HPNE-K-Ras, A549, Panc-1 and H460 were transfected as described for 
B and were analyzed for invasion through matrigel coated transwell inserts after 
24 hrs (HPNE cells), 48 hrs (Panc-1 and H460) or 72 hrs (A549). Experiment was 
done in triplicates and error bars show SD deviation between the different 
microscopic field. P value was calculated using the 3 values from the count and 
SD. Data are representative of two (HPNE and H549) or three (Panc-1 and H460) 
independent experiments. 
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hallmarks of cancer such as invasion and metastasis 
24
.  However, little is known about 
the regulation of survivin by mutant K-Ras and the contribution of survivin to mutant K-
Ras-mediated malignant transformation. 
In this manuscript, we used siRNA to knock down K-Ras expression in several 
human cancer cell lines and demonstrated that depletion of K-Ras reduces survivin 
protein levels in cancer cells that harbor mutant K-Ras but not wild type Ras.  In addition 
to decreasing the basal levels of survivin, depletion of K-Ras also inhibited the ability of 
paclitaxel and VP-16 to induce survivin, further confirming the importance of K-Ras in 
the maintenance of survivin.  Furthermore, the K-Ras depletion- mediated reduction in 
survivin levels was demonstrated in cancer cell lines from different tissue of origin. 
Therefore, our results suggest that the requirement of K-Ras expression for the 
maintenance of high levels of survivin in human cancer cells depends on the mutation 
status of K-Ras but is not tissue specific.  
Although our studies indicated that mutant K-Ras is required for the maintenance 
of survivin, they also clearly demonstrated that mutant constitutively active (CA) K-Ras, 
on its own, is not sufficient to induce survivin in several cell models including NIH-3T3 
murine fibroblasts and human kidney embryonic HEK293 cells as well as 2 human 
pancreatic cell lines C7 and HPNE.  Whether ectopic expression of CA-H-Ras can 
increase survivin levels is not clear with some studies showing that it can 
14, 15
, and other 
that it can not
16
. Consistent with our results, expression of CA-K-Ras in mouse kidneys in 
the Wilm’s tumour mouse model was not able to induce survivin25. Interestingly, in this 
model, expression of both CA-K-Ras and β-catenine was able to induce survivin25.  This 
study, coupled with our K-Ras depletion results, suggests that while several genetic 
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aberrations are required for increasing the levels of survivin, depletion of only K-Ras is 
able to decrease survivin.  Therefore, K-Ras is necessary for the maintenance of survivin 
but not sufficient to increase survivin levels. 
In addition to depleting the endogenous levels of survivin, our studies also 
demonstrated that depletion of K-Ras was able to decrease the levels of exogenous 
survivin whose ectopic expression was under the control of a foreign promoter.  This 
suggested that depletion of K-Ras may affect the stability of the survivin protein, and this 
was further confirmed by the demonstration that depletion of K-Ras increased survivin 
ubiquitination, and that treatment with the proteasome inhibitor Bortezomib 
compromised the ability of K-Ras siRNA to decrease the levels of the survivin protein.  
Therefore, our studies indicate that depletion of K-Ras leads to decreased survivin levels 
through a proteasome degradation mechanism.  Survivin has a fairly short half-life of 30 
min 
26
, and its stability has been suggested to depend on phosphorylation of survivin at 
T34 by CDK1 
22, 23
.  We have made the phophomimic T34D as well as the non-
phosphorylatable T34A survivin mutants and have demonstrated that depletion of K-Ras 
was as effective at decreasing the levels of these mutants as it was at decreasing the levels 
of wild type survivin, suggesting that the ability of K-Ras depletion to promote the 
proteasome degradation of survivin is independent of T34 phosphorylation.  While these 
results excludes the phosphorylation of survivin at T34 as the sole determinant of K-Ras 
regulated survivin stability, it doesn’t rule out possible involvement of this 
phosphorylation site in combination with other plausible K-Ras regulated mechanisms  
that are involved in the stability of survivin.  
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Depletion of K-Ras induces apoptosis in many human cancer cell lines that 
depend on mutant K-Ras for survival 
27, 28
.  However, whether this depends on the K-Ras 
depletion-mediated decrease in survivin levels is not known.  Using isogenic HCT-116 
colon cell lines, Sarthy et al
29
 have found that survivin depletion induces apoptosis 
preferentially in cancer cells that harbor mutant K-Ras.  However, several studies using 
RNAi screens have not all identified that depletion of survivin induces cell death in 
cancer cells with K-Ras mutation
27, 28
.  Consistent with this, our results also show that 
mutation of K-Ras alone may not predict sensitivity to survivin depletion. For example, 
depleting survivin in H460 and A549 but not in Panc-1 and MiaPaca 2 cells induces 
apoptosis, yet all 4 cell lines harbor mutant K-Ras.  Depletion of K-Ras may induce 
apoptosis through other mechanisms, and this may include the decrease in the levels of 
another IAP family member, XIAP, that we have observed in both Panc-1 and MiaPaca 2 
cells following K-Ras depletion. However, apoptosis following depletion of K-Ras in 
these 2 cell lines does not involve anti-apoptotic (Bcl-xL, Bcl-2 and Mcl-1) or pro-
apoptotic (Bax and Bad) Bcl2 family members (Figure 8). Depletion of K-Ras may cause 
global reduction in the levels of IAP family of proteins that may induce apoptosis.  Future 
studies that use a large number of cell lines that harbor mutant and wild type K-Ras are 
warranted to identify the effect of survivin depletion in the context of K-Ras mutation.   
Survivin has been associated with malignant transformation as its expression 
increases at early stages of tumor development and its targeted expression in skin 
predispose mice to UV induced tumors
30
.  Our studies show that, mutant K-Ras also 
depends on survivin for its ability to transform cells as well as to induce invasion. Using 
a genetically-defined pancreatic cancer cell model, we have shown that the ability of 
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mutant K-Ras to induce anchorage-independent cell growth on soft agar was inhibited by 
depletion of survivin.  Depletion of survivin also inhibited the anchorage-independent 
growth of human cancer cells that harbor mutant K-Ras such as Panc-1 and H-460 cells.  
Furthermore, the ability of mutant K-Ras to induce invasion in the genetically-defined 
HPNE pancreatic cell model was also inhibited by depletion of survivin. The ability of A-
549, H-460 and Panc-1 cancer cells, all of which harbor mutant K-Ras, to invade was 
also inhibited when survivin expression was knocked down. These results suggest that 
survivin may be critical to the ability of mutant K-Ras to induce metastasis.  This is 
consistent with recent studies that implicated survivin in invasion and metastasis
24
. 
Furthermore, the demonstration that depletion of survivin induce apoptosis in H460 and 
A549 but not in panc-1 cells, and that its depletion antagonizes soft agar growth and 
invasion in all three cell lines, suggests that the ability of survivin to regulate invasion or 
soft agar growth is independent of its ability to regulate apoptosis. 
In summary, this study identified an important  biochemical link between the 
protein product of one of the most frequently mutated gene in human cancer, K-Ras, and 
the stability of a protein that is almost exclusively expressed in cancer, survivin; and that 
this mutant K-Ras-survivin biochemical link contributes to K-Ras-driven malignant 
transformation.  
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Chapter 3 
 
Requirement of Ral GTPases for survivin expression is mutation- but not tissue-
specific 
 
Abstract 
Oncogenic K-Ras is known to induce malignant transformation by regulating 
several proteins that are important for abnormal proliferation and survival. Although 
previous studies have demonstrated the importance of survivin in Ras-mediated 
malignant transformation, the downstream effectors critical for this regulation are less 
studied. Here we show that, the small GTPase Ral, but not Akt or c-Raf, is critical for 
survivin expression in cancer cells that harbor mutant K-Ras. Furthermore, we show that 
Ral involvement in the regulation of survivin is mutation- but not -tissue specific. Indeed, 
Ral regulation of survivin requires mutant K-Ras and wild type p53, and the ability of Ral 
to regulate survivin depends on p53 that was induced following depletion of Ral. In 
summary we have identified Ral as a novel regulator of survivin and that this regulation 
is mutation- but not tissue-specific.  
Keywords: K-Ras, Ral, survivin, p53, cancer,  
Introduction  
Ras is a member of the Ras super family of small GTPases that plays a critical 
role in signal transduction
1
.  There are three Ras genes that encode four 21KDa Ras 
proteins, H-Ras, N-Ras, KA-Ras and KB-Ras.  These signal transducers act as switches 
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that are inactive when bound to GDP and active when bound to GTP.  For example, in 
normal cells when growth factors such as EGF bind their receptor, the receptors recruit 
complexes that contain guanine nucleotide exchange factors (GEF) such as mSOS-1 
which converts Ras-GDP (inactive) to Ras-GTP (active)
2
. In its GTP-bound active form 
Ras can bind over 20 known effector proteins and trigger a multitude of signal 
transduction pathways that are intimately involved in the regulation of cell division, 
proliferation, differentiation and survival
3
.   
Ras is mutated in about 30% of all human cancers. Mutation in amino acids 12, 
13 or 61
4
 are frequently observed and this results in a constitutively active (GTP-locked) 
Ras that remains persistently activate and hence activates several down stream effectors 
(see above).   
This aberrant activation of Ras mediates many of the hallmarks of cancer 
including uncontrolled cell division, sustained angiogenesis, metastasis and evasion of 
apoptosis.  The mechanisms by which mutant Ras contributes to these cancer hallmarks 
has been extensively studied but much remains to be investigated.  
Although Ras is known to engage over 20 effector proteins to regulate different 
malignant phenotypes, the Raf/MAPK, Pi3K/Akt, RalGDS/Ral pathways have been 
extensively studied:  Ras binds and activates the kinase Raf which in turn activates Mek 
to activate Erk
5
.  This so-called MAP kinase cascade has been implicated in uncontrolled 
proliferation of cancer cells.  Ras also binds and activates phosphatidylinositol kinase 
(Pi3K) which activates protein kinase B (Aka, Akt) which in turn triggers many pathways 
involved in tumor survival, angiogenesis and metastasis
6
.  Ras also bind the Ral GEF, Ral 
GDS, which in turn activates the small GTPase, RalA and RalB
7
.  Although early on the 
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Raf/Mek/Erk and Pi3K/Akt pathways were implicated, more recently the Ral 
GDS/RalA/B pathway has been shown to be just as important, and in some cases the only 
mediator, of Ras driven malignant transformation
8
. 
One of the major means by which mutant Ras causes malignant transformation of 
human cancer is by inhibiting apoptosis and promoting tumor survival
9
.  The mechanism 
by which Ras inhibits apoptosis and hence maintains tumor survival is not well 
understood.  Several mediators have been proposed such as Bcl2, cyclin D1, NFkb and 
others.  More recently, the small IAP survivin has been shown to be induced by mutant 
Ras and has been suggested as a mediator of Ras anti-apoptotic activity
10
.  Moreover, 
recently, we have found that depletion of K-Ras reduce survivin expression selectively in 
cells that harbor mutant K-Ras20. However the mechanism by which mutant Ras increases 
survivin levels is less known.  
H-Ras has been shown to increase survivin levels in a dexamethasone-inducible 
mutant CA-H-Ras system
10
.  In this rat cell system, survivin expression was modulated 
by the level of H-Ras expression.  The induction of survivin expression by H-Ras was 
cell cycle- and proliferation-independent. Furthermore, in Baf-3 cells, CA-H-Ras 
increased survivin levels in the absence of IL-3, whereas DN Ras suppressed the IL-3-
stimulated survivin increase
11
.  Similarly, in Hela cells CA-H-Ras induced sustained 
survivin expression during all phases of the cell cycle, and protected against drug-
induced apoptosis
12
.   
While the studies above suggested that H-Ras increased the levels of survivin and 
that this increase contributes to the ability of Ras to protect cancer cells from apoptosis, 
little is known about the mechanism by which Ras increases survivin levels.  In 
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particular, the signal transduction pathways downstream of Ras that mediate the up 
regulation of survivin are ill-understood.  The few studies that attempted to address this 
important question used only pharmacological inhibitors of Ras downstream effectors 
(see Figure 12).  
 
For example, one study showed that inhibitors of Mek, Pi3K and mTOR but not 
Akt inhibited the ability of CA-H-Ras to increase the levels of survivin in BaF-3 cells
11
.  
Similarly, in rat cells Mek and Pi3K inhibitors also inhibited CA-H-Ras-mediated 
survivin increase and apoptosis
10
.  However, in one study Pi3K inhibitors were unable to 
inhibit survivin levels. Finally, we have shown that geranylgeranyl transferase I inhibitors 
decreased the survivin levels in Mia-Pa-Ca-2 human pancreatic cancer cells, suggesting 
 
Figure 12. Inhibitors of Ras effecter pathways and survivin expression. 
The Pi3K inhibitor (LY294002) and  the MEK inhibitor (U0126) were shown to 
reduce H-Ras driven survivin expression. The geranylgeranyl transferase 
inhibitor (GGTI-2417) was shown to reduce survivin in a mutant K-Ras 
harboring cells.  
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geranylgeranylated proteins such as RalA and RalB may be involved in the regulation of 
survivin
13, 14
.  The drawback of these studies is that they used pharmacological inhibitors 
that may reduce survivin by off target effects. Moreover, the studies done so far 
investigated the downstream effectors of ectopically expressed H-Ras not endogenous K-
Ras. 
In summary, only a few studies investigated the role of these canonical 
downstream effectors in survivin expression that was induced by ectopic expression of H-
Ras but the role of these effectors in cancer cells in the context of mutant K-Ras has not 
been studied. Much investigation is needed to determine the mechanism by which Ras 
maintains survivin levels.  
Using different cancer cells from different tissue lineages and different genetical 
backgrounds, we have found that RalA and /or RalB is involved in the regulation of 
survivin expression only in cells with mutant K-Ras and wild-type p53 and the ability of 
Ral to regulate survivin in mutant K-Ras harboring cells depends on p53. 
Material and methods 
Cell culture 
Human tumor cell lines were grown in their respective media: A549 in Kaighn's 
modification medium (F12K) (Gibco Laboratories, Grand Island, NY), Calu-1 and 
SKOV-3 in McCoy’s 5a medium modified (Sigma-Aldrich, St.  Louis, MO), H460, 
AsPC-1, Ovcar-5 and BxPC-3 in RPMI, (Invitrogen, Carlsbad, CA), Panc-1, SW1990, 
and HOP-92 in Dulbecco’s modified minimal essential medium (DMEM) (Invitrogen). 
All cells were grown in their respective media containing 10% FBS and 1% penicillin/ 
streptomycin at 37
o
C in a humidified incubator at 5% CO2.  
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siRNAs and antibodies 
Non-targeting (NT), K-Ras, Raf-1, RalA and RalB siRNA were purchased from 
Dharmacon, Lafayette, CO, Akt1/2 siRNA was obtained from Cell Signaling (Danvers, 
MA) , respectively.  Survivin antibodies were purchased from Abcam, Cambridge, MA 
(used for western blotting). Akt1/2 and Raf-1 antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA).  Cleaved PARP antibody was purchased from Cell 
Signaling (Danvers, MA). β-actin, vinculin and α-tubulin antibodies were purchased from 
Sigma. K-Ras (OP-24), antibody was purchased from Calbiochem (Billerica, MA). 
Peroxidase conjugated goat anti-mouse IgG, rabbit anti-goat IgG, mouse anti-rabbit IgG 
antibodies were purchased from Jackson ImmunoResearch Laboratories (West Grove, 
PA).  
siRNA transfection 
Cells were transfected with siRNA using Lipofectamine RNAiMAX transfection 
reagent (Invitrogen) according to the manufacturer’s instructions. Briefly, cells were 
plated overnight to reach ~40-50% confluence at the time of transfection. Lipofectamine 
RNAiMAX and siRNAs were incubated with OptiMEM in separate tubes for 5 minutes, 
then the diluted transfection reagent and siRNAs were mixed.  The mixture was 
incubated at room temperature for 20 min. The siRNA/transfection reagent mixture was 
then added drop-wise to the cells. After 24 hrs of transfection, growth media with 10% 
serum only was added until the desired time of transfection.  
Western blotting 
Cells were rinsed with ice cold PBS twice and lysed on the plate using lysis buffer 
containing 20mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-
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100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerolphosphate, 1 mM sodium 
orthovanadate, 1ug/mL leupeptin, and 1 mM PMSF. The lysate was harvested by 
scraping and the debris was removed by centrifuging at 13000g for 13 min. The protein 
content was measured using Bradford protein assay. Samples were resolved using 12.5% 
SDS-PAGE and transferred to PVDF membranes (Millipore, Billerica, MA). The 
membranes were blocked with 5% milk in TBST (Tris-Buffered Saline and Tween 20) 
and then probed with the desired antibodies. The enhanced chemiluminescence blotting 
system (PerkinElmer Inc, Waltham, MA) was used for antibody reaction. 
Result 
Depletion of Ral but not Raf or Akt reduces survivin expression in cancer cells with 
mutant K-Ras. 
We have previously found that mutant K-Ras is required for the maintenance of 
high levels of survivin in cancer cells with mutant but not those with wild type K-Ras20. 
However, the downstream effectors of Ras critical for this regulation are not known. 
Although more than 20 downstream effectors of Ras are known so far, the RalGDS/Ral, 
Pi3K/AKT, Raf/Mek/Erk pathways were extensively studied for their role in Ras-driven 
signaling and malignant phenotypes. We therefore, determined which of the 3 pathways 
mentioned above is involved in the regulation of survivin in the context of mutant K-Ras. 
To this end, ovarian cancer cells that harbor mutant K-Ras (ovcar-5) and those that 
harbor wild-type K-Ras (Skov-3) were transfected by siRNA to deplete K-Ras, RalA, 
RalB, Akt, or c-Raf, and the effects of these depletions were determined by western 
blotting as described under Methods. Figure 13 shows that depletion of RalA or K-Ras 
reduces survivin in ovcar-5, whereas in in Skov-3 cells depletion of none of these genes  
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reduced survivin levels. This suggests that RalA but not RalB, c-Raf or Akt1/2 is critical 
for survivin expression in OVCAR-5 cells which harbor mutant K-Ras. 
Depletion of RalA or RalB fails to reduce survivin in pancreatic cancer cells. 
Persistent activation of RalGTPases has been reported in many tumors where 
mutations of K-Ras are prevalent. Since activated RalA and RalB are common in tumor 
of pancreatic origin
15
, we determined if depletion of these genes could reduce survivin in 
pancreatic cancer cells with and without mutant K-Ras. Our results (Figure 14) show that 
while siRNA to K-Ras, reduced survivin levels, RalA or RalB failed to reduce survivin 
levels in all human pancreatic cancer cells whether they harbor mutant or wild type K-
Ras. Therefore, we conclude that the presence of mutant K-Ras alone is not sufficient to 
predict if RalA or RalB can regulate survivin expression levels. 
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Figure 13. Depletion of RalA but not RalB, Raf or Akt reduce survivin in 
OVCA-5 cells which harbor mutant K-Ras. Ovcar-5 and Skov-3 cells were 
transfected with the indicated siRNA for 48hrs and the cell lysates were 
processed for western blotting where the membranes were probed with the 
indicated antibody as described in the material and methods section. 
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Depletion of RalA or RalB reduce survivin in subset of lung cancer cell lines 
Since we observed that RalA can regulate survivin expression levels in ovcar-5 
but not in any of the pancreatic cancer cell lines tested, we speculate that RalA 
contribution in survivin expression could be tissue specific. To this end, we took lung 
cancer cell lines with and without mutant K-Ras and investigate the effect of RalA or 
RalB depletion on survivin expression. Our result (Figure 15) show that, while depletion 
of RalA or RalB reduced survivin in H460 and A549 cells, depletion of Ral failed to 
reduce survivin levels in a other human lung cancer cell lines such as Calu-1 as well as 
those that harbor wt-K-Ras such as  HOP-92.  
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Figure 14. Depletion of RalA or RalB fails to reduce survivin levels in pancreatic 
cancer cells. The indicated pancreatic cancer cell lines were transfected with siRNA 
to NT, RalA, RalB or K-Ras for 48hrs and then process for western blot analysis.  
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While in H460, A549 and Ovcar-5 depleting RalA and/or RalB reduced survivin 
levels, in calu-1 and all the pancreatic cell lines we tested, depleting Ral had no 
significant effect on survivin levels, yet all these cell lines harbor mutant K-Ras. Our 
finding suggests that the regulation of the survivin expression levels by Ral proteins is 
not tissue specific nor it is exclusively associated with the K-Ras mutation status of the 
cells. This suggests that other factors may be involved in this regulation of survivin by 
Ral. To this end, we looked at the mutation status of different genes to see if other 
additional mutations can potentially affect the ability of Ral to regulate survivin 
expression. Our analysis shows that, all cell line where we observe Ral involvement in 
survivin expression, had in common mutant K-Ras and wild type p53 (see table 2). We 
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Figure 15. Depletion of K-Ras, RalA or RalB reduces survivin in subset of 
lung cancer cell lines. Lung cancer cells with or without mutant K-Ras were 
transfected with the indicated siRNA for western blot analysis and membrane were 
probed with the indicated siRNA.  
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therefore conclude that, in addition to the K-Ras mutation status of the cell, the p53 status 
of a cells may determines the ability of Ral to regulate survivin.  
Table 2. Mutation analysis revels that, involvement of Ral in survivin expression is 
mutation- but not tissue-specific 
 
                 
K-ras p53
Lung A549 MT WT RalB
Lung H460 MT WT RalA
Lung Calu-1 MT Deleted NO
Lung Hop-92 WT MT NO
Ovary SKOV-3 WT MT NO
Ovary Ovcar-5 MT WT RalA
Ovary Tov-21G MT WT RalA
Pancreas MiaPaca-2 MT MT NO
pancreas Panc-1 MT MT NO
pancreas SW1990 MT MT NO
pancreas BX-PC-3 WT MT NO
Does depletion of 
Ral affect survivin?
Mutation status  
Cell lineTissue
 
The ability of Ral to regulate survivin depends on the presence of p53 and mutant K-
Ras. 
p53 is well known transcription factors that affect the expression of different gens 
that are known to be involved in apoptosis and cell cycle regulation. Since previous 
studies have shown negative regulation of survivin expression by wild-type p53
16
 and 
lower survivin levels in tumors with wild-type p53
17
, we speculate that K-Ras or Ral 
GTPases influence survivin expression in a p53-dependent manner. We therefore 
hypothesize that, depletion of K-Ras or RalA or RalB may lead to increases in p53 
expression levels and subsequently the induced p53 will interfere with survivin 
expression. To determine if p53 plays a role in Ral regulated survivin, we co-deplete K-
Ras, RalA or RalB with siRNA to p53 and ask if co-depletion of the genes rescue 
survivin expression. For this, we took A549 cells that have mt-K-Ras and WT-p53 and 
used siRNA to K-Ras, RalA or RalB alone or in combination with p53. Our result (Figure 
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16) show that, while siRNA to K-Ras or RalB reduced survivin levels, co-depletion of K-
Ras or RalB with p53 rescued from the reduction of survivin following K-Ras or RalB 
depletion in A549 cells.  
 
Discussion 
The role of Ras in malignant transformation is well documented and the 
contributions of different proteins in Ras-induced malignant transformation have been the 
focus of intense scrutiny by different groups. To date, there are no FDA approved Ras 
inhibitors in clinic and hence researchers have been working at identifying alternative 
ways to disable Ras-driven malignant transformation. Some of these approaches include 
identifying targets downstream of Ras that are drugable.  
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Figure 16. The ability of Ral to regulate survivin depends on p53 and on mutant 
K-Ras. A549 cells were transfected either with siRNA to NT, K-Ras, RalA or RalB 
alone or in combination with p53 for 48hrs and membrane was probed with the 
indicated antibody. The graph on the right panel shows the normalized densitometry 
values of p53 from the western blot in the left panel. 
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Recently, we have demonstrated that K-Ras is required for the maintenance of the 
high levels of survivin in human cancer cells that harbor mutant K-Ras but not in human 
cancer cells where Ras is wild type20 and Chapter 2 of this thesis. These studies also 
showed that depleting survivin reduces mutant K-Ras-driven anchorage-independent 
growth and invasion.  However, the K-Ras downstream effectors involved in survivin 
regulation are not known. Here we investigated the role of three known downstream 
effectors of Ras in the maintenance of high survivin levels in the context of mutant K-
Ras. The Raf/Mek/Erk, Pi3K/Akt, and RalGDS/Ral pathways are three known canonical 
downstream effectors that have been extensively studied with regards to their roles in 
mediating Ras-driven malignant transformation.  Although, initially the Raf/Mek/Erk and 
Pi3K/Akt pathways were thought to be the most critical, more recently the RalGDS/Ral 
pathway has been shown to be more important in mediating Ras-driven malignant 
transformation in some cancer cells  
To investigate the role of these three downstream pathways in regulating survivin 
protein levels in the context of mutant K-Ras, we individually depleted c-Raf, Akt, RalA 
and RalB by siRNA in two ovarian cancer cell lines, one that harbors mutant K-Ras 
(ovcar-5) and the other that harbors wild type Ras (skov-3). Our study shows that 
depleting K-Ras and RalA but not RalB, Akt, or c-Raf reduces survivin in ovcar-5 but not 
in skov-3 cell line. Our study suggests that RalA but not the other downstream effectors 
of Ras were critical to K-Ras regulation of survivin. Previous studies have used 
pharmacological inhibitors to explore the role of Raf/Mek/Erk and Pi3K/Akt in survivin 
expression
10-12
. The studies however show inconsistent findings when different cell lines 
were used. While cell type differences remain a possible reason for these inconsistencies, 
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it is also possible that off target effects from the drugs could explain these 
inconsistencies. We therefore used a genetic approach, such as depletion of the genes by 
siRNA to reduce off-target effect and to investigate the pathways of interest in a more 
precise and defined pathway. 
Persistently activated, GTP-bound Ral has been found in many tumors where 
mutation of K-Ras is also prevalent
15, 18
. Since depletion of RalA reduces survivin in the 
mutant K-Ras harboring ovarian cancer Ovcar-5 cells, we investigated the role of Ral in 
human pancreatic cancer cells where previous studies show the presence of activated Ral.  
Surprisingly, despite the presence of mutant K-Ras in these cancer cell lines, depletion of 
RalA, RalB, Akt and c-Raf did not reduce survivin levels. These results suggest that the 
involvement of Ral could be cell/tissue specific. Indeed previous studies have shown 
differential role of Ral in cancers from different tissues of origin
15, 18
. Although Ral 
proteins share approximately 80% sequence identity overall, and 100% sequence identity 
at their effector domains 
19
, these small GTPases have been shown to bind to different 
effectors and mediate different malignant phenotypes in different tissues. Lim et al have 
shown that in pancreatic cancer RalA promote anchorage-independent growth and in vivo 
tumor growth, RalB was shown to be involved in apoptosis and migration
15
. In colorectal 
carcinoma however, while RalA promote similar phenotypes as in pancreatic cancer, 
RalB actually antagonizes the effector RalA
18
. The differential effect observed in these 
cell lines were partly due to their binding to different effectors. While RalA binds to Exo-
8 to promote the above-mentioned phenotypes, RalB binds to sec-5 to antagonize the 
effect driven by RalA. We therefore speculated that  Ral GTPase regulation of survivin 
expression could be tissue specific. However, our depletion studies in several lung cancer 
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cell lines argued against a tissue-specific effect.  Indeed, depleting RalA and/or RalB 
reduced survivin levels only in a subset of lung caner cell lines tested.  
Consistently throughout our study, we have found that regardless of the tissue of 
origin, depletion of Ral proteins fails to affect survivin levels in wt-K-Ras harboring 
cancer cell lines. Interestingly, in this study we have also observed that despite the 
differences in tissue of origin, depletion of RalA and/or RalB decreased survivin levels 
only in cell lines that harbor mutant K-Ras. Furthermore, in pancreatic cancer cell lines 
where p53 is mutated as well as in the lung cancer calu-1 cells where p53 is deleted, 
depletion of RalA or RalB fails to reduce survivin levels.  However, in other lung cancer 
cell lines, H460 and A549, depletion of RalA and/or RalB reduces survivin levels. We 
conclude that neither tissue of origin or mutation of K-Ras is sufficient to predict whether 
depletion of Ral proteins will result in reduction of survivin levels, and that other factors 
may be involved.  
A closer look at the mutation status of these cell lines lead us to discover that 
depletion of Ral proteins reduces survivin levels only in human cancer cell lines that 
harbor mutant K-Ras and wild type p53, but not in those cell lines with wilt type K-Ras 
and/or mutant p53. This observation is consistent with previous reports that showed that 
WT but not mutant p53 regulates the expression of survivin. Our recently  published 
work demonstrated that depletion of K-Ras reduces  survivin levels only in human cancer 
cells that harbor mutant K-Ras, regardless of the mutation status of p53.  Furthermore, 
depletion of K-Ras in calu-1 cells where both p53 alleles are depleted reduced survivin 
levels further supporting a p53-independent mechanism. However, in A-549 cells where 
p53 is wild type, siRNA to p53 prevented the reduction in survivin following K-Ras 
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depletion (see chapter 4 of this thesis), suggesting that K-Ras may regulate survivin in 
p53 dependent and independent manner. Similar mode of regulation for the expression of 
p21 has been demonstrated previously. While K-Ras appears to regulate survivin in p53- 
dependent and -independent manner, Ral proteins seem to dependent on wild type p53 
and mutant K-Ras to regulate Survivin. Consistent with this conclusion is the observation 
that depleting Ral proteins failed to reduce survivin in all cell lines that harbor mutant 
p53 despite the presence of mutant K-Ras. Similarly, Ral depletion failed to reduce 
survivin levels in cell lines that express  WT-K-Ras and WT-p53. More direct evidence 
for the dependence on p53 comes from the observation that siRNA to p53 rescues from 
survivin reduction following Ral depletion. We therefore conclude that Ral involvement 
in the regulation of survivin depends on the mutation status of the cells and requires the 
presence of mutant K-Ras and WT-p53. 
In summary, our study used a large number of cell lines to investigate the 
pathways downstream of K-Ras that are critical for the regulation of survivin expression 
in the context of mutant K-Ras. Our study took advantage of using cancer cell lines that 
harbor mutant K-Ras naturally instead of relying on artificial over expression that would 
potentially cause stress on the cells and alter their normal behavior. Furthermore, our 
studies lead to the discovery of the involvement of Ral GTPases, but not Akt or Raf, in 
the regulation of survivin, a known protein that is involved in resistance to apoptosis and 
promotion of cell cycle progression. An important finding of this work is the dependence 
on mutant K-Ras and wild type p53 for the Ral regulation of survivin.  
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Chapter 4 
 
Ral GTPase down regulation stabilizes and reactivates p53 to inhibit malignant 
transformation 
Abstract 
Ral GTPases are critical effectors of Ras, yet the molecular mechanism by which 
they induce malignant transformation is not well understood. Here we show that down 
regulation of K-Ras, RalA and RalB, but not Akt1/2 and c-Raf, leads to p53 Ser-15 
phosphorylation and a significant increase in p53 half-life.  This increased stability 
results in a p53-dependent up-regulation of p21waf and mdm2 and down-regulation of 
survivin expression.  Furthermore, depletion of Ral GTPases inhibits cell cycle 
progression, anchorage-independent growth and/or invasion in a p53-dependent manner. 
Thus, expression of Ral proteins is critical to maintaining low levels of p53, and down 
regulation of Ral GTPases reactivates p53 by significantly enhancing its stability, and 
this contributes to suppression of malignant transformation. 
Introduction 
Malignant transformation is a complex process that involves constitutive 
activation of proto-oncogenes and inactivation of tumor suppressor genes 
1
.  The Ras 
family members K-, N- and H-Ras are proto-oncogenes that are mutated and 
constitutively activated in one third of all human cancers, with K-Ras mutations being the 
most prevalent 
2
.  Mutant Ras proteins induce malignant transformation by persistently 
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activating several down stream pathways 
3
.  Among the most thoroughly studied 
downstream effectors of Ras proteins are those mediated by the Raf/Mek/Erk, the 
Pi3K/Akt, and the RalGDS/Ral pathways.  These 3 pathways have been shown to be 
required for Ras proteins to induce certain hallmarks of cancer such as uncontrolled 
proliferation, apoptosis evasion, angiogenesis, migration and invasion 
3
.  In addition to 
activating pathways that promote oncogenesis, mutant Ras proteins also antagonize 
tumor suppressive pathways to transform cells.   
The tumor suppressor p53 is the genome guardian that prevents malignant 
transformation by inducing cell cycle arrest, senescence and apoptosis in response to 
stress signals such as oncogene activation 
4, 5
 and DNA damage 
6, 7
.  p53 is a transcription 
factor that induces or represses the expression of many genes including those involved in 
cell cycle progression and cell survival 
8 
.  Most human tumors contain non-functional 
p53, either because of p53 mutations or inactivation of p53-dependent pathways 
4, 9
.  One 
mechanism by which tumors with wild type p53 inactivate it is by over expressing its 
negative regulator mdm2, an E3 ligase that induces p53 degradation 
10
. Another 
mechanism by which wild type p53 is inactivated is by loss of the mdm2 antagonist ARF 
11-13
. Therefore, for oncogenes to transform cells with wild type p53 they must trigger 
pathways that lead to the inactivation of p53.  In the case of the Ras proteins this is 
isoform-dependent 
14-17
.  Cells challenged with mutant H-Ras or mutant N-Ras protect 
them selves by inducing the expression of ARF 
18-20
 which antagonizes MDM2 function 
either by sequestering MDM2 in the nucleoli 
13
 or by directly inhibiting its ubiquitin 
ligase activity 
11
.  This leads to increased p53 levels which in turn lead to senescence and 
apoptosis 
5
.  In contrast, mutant K-Ras suppresses p53 
16
 but the mechanism involved is 
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not well understood.  One proposed mechanism involves the activation of the E3 ligase 
SNAIL which leads to ubiquitination of p53 and its proteasomal degradation
16
.  
Although not thoroughly investigated, some studies reported on the regulation of 
p53 by downstream effectors of Ras such as Raf and Akt but not Ral proteins.  For 
example, in Ras-transformed cells, Raf promotes the degradation of p53 by inducing 
mdm2 and this leads to resistance to p53-dependent apoptosis following DNA damage
21
.  
Furthermore, Akt phosphorylates mdm2 on S186 which leads to ubiquitination and 
degradation of p53 
22
 .  Whether Ral proteins regulate p53 and whether this contributes to 
malignant transformation have not been investigated.   
RalA and RalB GTPases are molecular switches that are on (active) when bound 
to GTP and off (inactive) when bound to GDP 
23
. RalGEFs such as RalGDS displace 
GDP for GTP to activate Ral proteins 
24
. Ral proteins can be activated by Ras as well as 
by other pathways that are independent of Ras 
25, 26
 . The interest in Ral proteins has 
recently increased following the demonstration that in some cancers Ral proteins are 
more critical than Raf and Akt in mediating Ras-driven malignant transformation 
27
.  
RalA and RalB share ~82% sequence identity, yet they have been shown to have 
different contributions to malignant transformation processes, but this is cancer cell type 
specific
28-32
.  For example, in pancreatic cancer cells, RalA promotes anchorage-
independent growth in soft agar and tumor growth in-vivo while RalB promotes cell 
survival, invasion and migration
29
. In colon cancer cells, Ral A has similar functions as in 
pancreatic cancer cells but RalB antagonizes RalA-driven anchorage-independent growth 
30
 .  The reasons for these divergent effects are not known but differences in localization 
32
  and post- translational modifications 
28, 31, 32
 could be contributing factors.   
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Although Ral proteins have been shown to induce many hallmarks of cancer such 
as anchorage-dependent and -independent growth, migration and invasion
33, 34
, the 
molecular mechanism by which they accomplish this is not well understood.  In addition, 
whether Ral proteins antagonize tumor suppressive pathways to transform cell is not 
known.  For example, whether Ral proteins regulate the levels of the tumor suppressor 
p53 and whether this contributes to their ability to induce malignant transformation are 
not known. In this manuscript, we demonstrate that depletion of Ral proteins increases 
p53 ser-15 phosphorylation and leads to a significant increase in p53 half-life and 
stability.  In addition, depletion of Ral proteins inhibits malignant transformation in a 
p53-dependent manner.  Taken together, these results suggest that down regulation of Ral 
GTPases leads to stabilization and reactivation of p53 to inhibit malignant transformation 
of cancer cells that harbor wt p53 and mt K-Ras. 
Material and methods  
Cell culture 
The human tumor cell lines were grown in their respective media: H460, MCF-7, 
Ovcar-5 and BxPC-3 in RPMI, (Invitrogen, Carlsbad, CA), A549 in Kaighn's 
modification medium (F12K) (Sigma Aldrich, St.  Louis, MO), Calu-1 in McCoy’s 5a 
medium modified (Sigma-Aldrich, St.  Louis, MO), Panc-1, HCT116 and HKH2 in 
Dulbecco’s modified minimal essential medium (DMEM) (Invitrogen, Carlsbad, CA). 
All cells were grown in their respective media containing 10% FBS and 1% penicillin 
streptomycin at 37
o
C in a humidified incubator at 5% CO2.  
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siRNAs and antibodies 
Non-targeting (NT), K-Ras, RalA, RalB, p53 and p21, c-Raf siRNA were 
purchased from Dharmacon (Lafayette, CO) and Akt 1,2,3 siRNA were purchased from 
Cell Signaling (Danvers, MA).  Survivin antibody was purchased from Abcam 
(Cambridge, MA). p21, c-Raf, p53 (DO-1), and Akt1/2 antibodies were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA).  Cleaved PARP and phospho-p53 (Ser-15) 
antibodies were purchased from Cell Signaling. RalB and MDM2 antibody was 
purchased from Millipore (Billerica, MA). β-actin, vinculin, α-tubulin and GAPDH 
antibodies were purchased from Sigma-Aldrich. K-Ras (OP-24) antibody was purchased 
from Calbiochem (Billerica, MA). RalA antibody was purchased from BD Biosciences, 
(Bedford, MA), Peroxidase-conjugated rabbit anti-goat IgG, goat anti-mouse IgG, and 
mouse anti-rabbit IgG antibodies were purchased from Jackson ImmunoResearch 
Laboratories (West Grove, PA). 
siRNA transfection 
All cells used in this manuscript were transfected with a similar siRNA 
transfection protocol using Lipofectamine RNAiMAX transfection reagent (Invitrogen, 
Carlsbad, CA). The cells were plated overnight to reach ~40-50% confluence at the time 
of transfection. Opti-MEM reduced serum medium (Invitrogen) and Lipofectamine 
RNAiMAX were mixed in one tube and a mixture of Opti-MEM and siRNA was 
prepared in a separate tube, and the content of the two tubes were mixed after 5 minutes 
of incubation at room temperature.  Following this, the mixture was incubated for 20 
minutes at room temperature and then added to the cells drop-wise. After 24 hours of 
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transfection, appropriate media with 10% serum only was added until the desired time of 
transfection. 
DNA transfection 
Cells were plated overnight to reach 70-80% confluence and transfected with 
DNA using Lipofectamine 2000 transfection reagent (Invitrogen) according to the 
manufacturer’s instructions.  Briefly, Lipofectamine 2000 reagent (1.5μl/μg of DNA) was 
diluted in Opti-MEM and allowed to equilibrate for 5 minutes at room temperature. DNA 
was diluted in Opti-MEM in a separate tube. The contents of the two tubes were mixed 
and incubated for 20 minutes to complex at room temperature, then added drop wise to 
cells that contain only 10% FBS containing regular growth media. The cells were 
transfected for 6 hours before changing the medium to 10% FBS only regular growth 
media.  
Western blotting 
Cells were rinsed with ice-cold PBS twice and lysed on the plate in lysis buffer 
containing 20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton 
X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerolphosphate, 1 mM sodium 
orthovanadate, 1µg/mL leupeptin, and 1 mM PMSF. The lysate was collected by scraping 
and centrifuging at 13000xg for 13 minutes to remove the debris. The protein content was 
measured using Bradford protein assay. Samples were resolved using SDS-PAGE and 
transferred to PVDF membranes (Millipore). The membranes were blocked with 5% milk 
in Tris-buffered saline and Tween-20 (TBST) and then probed with the desired 
antibodies. Western Lightning ECL (PerkinElmer Inc, Waltham, MA) was used for 
antibody detection. 
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Caspase activation assay 
Caspase-3 activity was measured in cell lysates using a fluorogenic substrate. The 
assay measures the cleavage of AMC groups from a Caspase-3 specific substrate (Ac-
DEVD-AMC) (Biomol Research Labs, Inc., Plymouth Meeting, PA). Briefly, cells were 
lysed in a protease inhibitor-free lysis buffer (50 mM Tris, pH 8, 5 mM EDTA, 150 mM 
NaCl, and 0.5% Igepal). The lysate was collected by scraping. After clearing the lysate 
by centrifugation, protein was measured. 20 μg of protein and 20 μM caspase-3 substrate 
were added into 50 mM Tris, pH 7.5 reaction buffer in triplicate in a 96-well plate. The 
reactions were incubated for 1 hour at 37
o
C and liberated AMC groups were quantified 
by a fluorometer (WALLAC Victor 1420 Multilabel counter, Perkin Elmer Life Sciences, 
Turku, Finland) with 355 nm excitation and 460 nm emission filters.  
Soft agar colony formation assay 
A549 and H460 cells were transfected with siRNA for 48 hours, then the cells 
were trypsinized, counted and 2,000 cells/well were seeded in triplicate in 12-well culture 
plates in 0.3% top agar over 0.6% bottom agar layer as previously described. Cultures 
were incubated for two weeks (H460) or three weeks (HCT116). Plates were scanned 
after overnight incubation with 2 mg/ml MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, Calbiochem), in phosphate buffered saline. The colony 
numbers were visually determined and quantified.  
Cell invasion assay 
Analysis of cell invasion was performed using 24-well Matrigel invasion 
chambers (8 µM pore size, BD Biosciences, Bedford, MA) according to the 
manufacturer’s instructions. Briefly, the inserts were rehydrated by adding warm serum-
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free medium for 2 hours at 37
o
C, 5% CO2 atmosphere. The medium was then removed 
from the inserts, and 750 µl of medium containing 20%FBS was added to each well of 
the plate and the inserts were placed on top of the medium. Transfected A549, Panc-1, 
and H460 (40,000 cells in 500 µl of serum free-media) and HPNE cells (20,000 cells) 
were added to the inserts. The cells were incubated for 48 hours at 37
o
C. Cell invasion 
was determined by staining the bottom of the insert with crystal violet (0.5% crystal 
violet in 25% methanol). The porous membrane was removed and placed on the slide. 
The number of cells that invaded were counted in three high-power microscope (40X) 
fields and averaged as the mean number of invaded cells per field for each membrane.  
Promoter-reporter transcriptional assay 
To determine the effect of K-Ras, RalA or RalB depletion on p21 promoter 
activity, 300,000 H460 or A549 cells were plated overnight, in triplicate, in 6-well plates 
followed by 3 μg of p21 and (1:50 b-gal) transfection using Lipofectamine 2000 (as 
described above). 12hrs after DNA transfection, the cells were then transfected with 
different siRNAs using Lipofectamine RNAiMax or using Lipofectamine 2000 as 
described above. Following 48 hours of siRNA or DNA transfection, cells were rinsed 
with PBS and then lysed on the plate using Reporter Lysis Buffer (RLB) as described by 
the manufacturer (Promega BioScience, San Luis Obispo, CA). Cells were then freeze-
thawed for efficient lysis. The lysate was centrifuged at 12,000g for 2 minutes to remove 
debris.  The p21 promoter activity was detected by incubating the lysate with the assay 
substrate. The luciferase activity was detected using a TD-20/20 luminometer (Turner 
Designs, Sunnyvale, CA) and b-galactosidase was read at 420nm wave lenght using Biot-
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Tek plate reader The p21 promoter activity was normalized to the respective b-
galactosidase reading.  
Determination of p53 half-life 
H460 or A549 cells were transfected with siRNA. Following 48 hours of 
transfection, cells were treated with 50 µg/mL of cyclohexamide for 0, 0.5, 1, 2, or 4 
hours and then harvested and processed for western blot analysis as indicated above. 
Cell cycle analysis 
A549 cells were transfected with different siRNAs for 48 hours. Following 
completion of siRNA transfection, cells were trypsinized and then centrifuged at 200xg 
for 5 minutes to harvest the cells. The cells were then rinsed with PBS twice and then re-
suspended in ethanol overnight. Following overnight fixation, cells were then 
centrifuged. The supernatant was removed and rinsed with PBS. The cells were stained 
with propidium (PI) iodide stain that contain 20ug/mL PI, 0.1%(v/v) Triton in PBS and 
0.2mg/mL DNAase free RNAase A for 2 hours at room temperature. Cells distribution on 
different cell cycle phase was determined using a flow cytometer.  
Cell lines 
The human cancer cell lines Calu-1, Panc-1, A549, BxPC-3, H460, HCT116, 
MCF-7 and Ovcar-5 were all obtained from ATCC but none of the cell lines have been 
authenticated. 
Results 
Expression of K-Ras, RalA or RalB, but not AKT1/2 or c-Raf, is required for 
the maintenance of low levels of p53 in human cancer cells that harbor mutant K-Ras 
and wild type p53 
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  About half of human cancers lack the tumor suppressive activity of p53 due to 
gene deletions or mutations
9, 35-38
 . The other half that express wild type (wt) p53 harbor 
aberrant pathways that either inactivate p53 or suppress its expression levels 
9, 35-38
 . 
Mutant (mt) K-Ras is known to down regulate wt p53 levels but little is known about the 
contributions of its down stream effectors.  For example, Ral GTPases are critical 
mediators of K-Ras-driven malignant transformation but whether they regulate wt p53 is 
not known.  To address this important question, we first determined whether depletion of 
Ral GTPases affects the expression levels of p53 in A549 and H460 cell lines that harbor 
mt K-Ras and wt-p53.  Since Akt and Raf are also critical to Ras malignant 
transformation, we also investigated the effects of their depletion on the expression levels 
of p53. To this end, A549 and H460 cells were transfected with either non-targeting 
siRNA or siRNAs to K-Ras, RalA, RalB, AKT1/2 or c-Raf and the cells were processed 
for western blotting as described under Experimental Procedures. Figure 17 shows that in 
both A549 and H460 cells depletion of K-Ras, but not Akt1/2 and c-Raf, resulted in 
increased p53 levels.  Depletion of RalB in both cell lines also increased p53 and this 
increase was more pronounced (3.5-fold for both A549 and H460) than with K-Ras 
depletion (1.6 (H460) and 2.4 (A549)-fold).  Furthermore, depletion of RalA increased 
the levels of p53 in H460 but had little effect in A549 (Figure 17). To determine if the 
increase in p53 levels is dependent on the mutation status of K-Ras and p53, we used 
other cell lines with mt K-Ras and wt p53 (HCT116 colon cancer cells and OVCAR5 
ovarian cancer cells), wt K-Ras and wt p53 (MCF7 breast cancer cells and HCT116 cells 
where the mutant K-Ras was deleted by homologous recombination (HKH2 cells), wt K-
Ras and mt p53 (BXPC3 pancreatic cancer cells), and mt K-Ras and mt p53 (Panc1 
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pancreatic cancer cells).  Figure 18 shows that depletion of K-Ras, RalA and RalB 
increased p53 levels in cells with mt K-Ras and wt p53 (HCT116 and OVCAR5) but  
 
not in cells with either wt K-Ras and/or mt p53 (MCF7, BXPC3 and Panc1).  
Furthermore, depletion of K-Ras, RalA and RalB in the isogenic cell line HCT-116 
(HKH-2) where the mutant K-Ras allele was deleted had little effect on the levels of p53 
(Figure 18).  Therefore, our results suggest that in human cancer cells that harbor mt K-
Ras and wt p53, the expression of K-Ras, RalA and/or RalB is required for the 
maintenance of low levels of p53.   
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Figure 17. Depletion of RalA and/or Ral B increases p53 protein 
levels in cancer cells with WT-p53 and mt-K-Ras.  A. Depletion of RalA 
and/or Ral B but not AKT1/2 or c-Raf affects p53 expression in cells with 
mt-K-Ras and wt-p53. H460 and A549 cells were transfected with the 
indicated siRNA for 48hrs and processed for western blotting analysis as 
described in the material and method section. 
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Depletion of K-Ras, RalA and RalB leads to up-regulation of p21 and down-regulation 
of survivin expression in a p53-dependent manner 
p53 controls cell cycle progression and cell survival by regulating at the 
transcriptional levels the expression of several genes that are involved in cell cycle 
progression (e.g. p21) as well as those involved in apoptosis (e.g. survivin) 
39-42
.  
Therefore, we next determined whether Ral GTPases are involved in the regulation of 
these genes and whether this is dependent on p53.  Figure 19A shows that in A-549 cells, 
depletion of K-Ras and RalB increased the protein levels of p53 and p21.  Consistent 
with this, depletion of K-Ras and RalB also increased the p21 promoter transcriptional 
WT-K-Ras/mt-p53
BXPC-3Panc-1
mt-K-Ras/mt-p53
siRNA
MCF-7
WT-K-Ras/WT-p53
HCT116
p53
RalB
K-Ras
Actin
RalA
mt-K-Ras/WT-p53
N      K        A       B
Ovcar-5
1       3.7     2.6    2.91       1.8     2.3    1.7
N      K        A       B N      K        A       B N      K        A       B N      K        A       BNT   K      A       B
HKH-2
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Figure 18. Depletion of K-Ras, RalA or RalB increase p53 expression 
selectively in cells with mutant K-Ras and wild-type p53. Cancer cells that 
harbor mt K-Ras and wt p53 (HCT116 colon cancer cells and OVCAR5 
ovarian cancer cells), wt K-Ras and wt p53 (HKH2, MCF7 breast cancer 
cells), wt K-Ras and mt p53 (BXPC3 pancreatic cancer cells) and mt K-Ras 
and mt p53 (Panc1 pancreatic cancer cells) were transfected with the 
indicated siRNA for 48hrs and processed for western blotting analysis as 
described in the Experimental Procedures section.  Data are representative of 
three (A549, H460 and HCT116) or two (Ovcar-5, panc-1, HKH2, MCF-7 and 
BxPC-3) independent experiments. (N, K, A and B designate Non targeting, 
K-Ras, RalA and RalB siRNA, respectively). 
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Figure 19.  Depletion of K-Ras, RalA and Ral B regulate survivin and p21 
expression in a p53-dependent manner. A. (A549) and C. (H460) cells were 
transfected with NT, K-Ras, RalA or RalB siRNA alone or in combination with p53 
siRNA for 48hrs. Cells were harvested for western blot analysis as described in 
the material and method section.  B. (A549) and D. (H460) cells were transfected 
with p21 promoter-reporter constructs followed by transfection with the indicated 
siRNA. Cells were harvested and analyzed for p21 promoter activity as described 
in the Experimental Procedures sections. E. Calu-1 cells were transfected with the 
indicated siRNA and processed for western blotting analysis as described in the 
Experimental Procedures section. Extra lane on p53 and p21 blot were from a 
control lysate (Panc-1 cells) used as a control for the western blot analysis.  Data 
are representative of three independent experiments except for Calu-1 cell 
experiments that were done twice  
 
106 
 
activity (Figure 19B). Furthermore, Figure 19A also shows that depletion of K-Ras and 
RalB decreased the levels of survivin.  In H460 cells, depletion of K-Ras, RalA and RalB 
increased p21 expression at the protein (Figure 19C) as well as the transcriptional (Figure 
19D) levels.  We next determined whether this increase in p21 and decrease in survivin 
levels are dependent on the expression of p53.  To this end, we took two approaches. 
First, since depleting K-Ras, RalA and RalB increased p53 levels, we reasoned that co-
depleting p53 should rescue if the effects are p53-dependent. Therefore, we transfected 
A549 and H460 cells with K-Ras, RalA or RalB siRNAs alone or in combination with 
p53 siRNA and evaluated the levels of p53, p21 and survivin as described under 
Experimental Procedures.  Figures 19A and 19C show that K-Ras, RalA and RalB 
siRNAs were unable to decrease survivin and/or increase p21 protein levels in the 
absence of p53.  Similar results were obtained with p21 promoter transcriptional activity 
(Figures 19B and 19D). In the second approach we used a cell line where K-Ras is 
mutated and both p53 alleles are deleted (human lung cancer calu-1 cells) and determined 
the effects of depleting K-Ras, RalA and RalB.  Figure 19E shows that depletion of RalA 
and RalB failed to increase p21 and to decrease survivin expression levels. In contrast, 
depletion of K-Ras decreased the levels of survivin but was unable to increase the levels 
of p21, suggesting that in calu-1 cells the ability of K-Ras to regulate p21 but not survivin 
is p53-dependent.  
Depletion of RalA and RalB increases p53 Ser-15 phosphorylation and p53 stability 
and half life 
Figures 17,18 and 19 demonstrated that depletion of Ral GTPases increased the 
amount of functional p53 protein in human cancer cells with mt K-Ras and wt p53, and 
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that this resulted in the modulation of p53-regulated genes such as p21 and survivin.  We 
next determined whether the increase in p53 levels is due to increased stability of the p53 
protein.  To this end,  H460 cells were transfected with either non-targeting (NT) siRNA 
or siRNA to K-Ras, RalA or RalB for 48 hours followed by treatment with 
cyclohexamide (CHX) for 0, 0.5, 1, 2 or 4 hrs and the cells processed for western blotting 
as described under Experimental Procedures.  Figure 20 and Figure 21 show that in cells 
transfected with NT siRNA, the protein levels of p53 decreased steadily after treatment 
with CHX with a half-life between 30 and 60 minutes.  
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Figure 20. Depletion of K-Ras, RalA and RalB increases p53 protein stability.   
H460 cells were treated with non targeting, K-Ras, RalA or Ral B siRNA for 48 hrs 
followed by cyclohexamide treatment for the indicated lengths of time. Cells were 
harvested and processed for western blotting analysis as described in the 
Experimental Procedures section.  Data are representative of two independent 
experiments. 
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In cells transfected with RalA, RalB or K-Ras siRNA,  p53 protein levels 
decreased after CHX treatment but at a much slower rate with half-lives  greater than 4 
hrs (RalA and RalB siRNAs) and greater than 2 hrs (K-Ras siRNA) (Figure 20 and 
Figure 21). Thus, in the absence of RalA and RalB, p53 half-life was increased by 
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Figure 21. Densitometer values of p53 and MDM2 proteins. Densitometer 
values represent the expression levels of p53 and MDM2 following depletion of 
K-Ras, RalA or RalB. The expression levels of p53 and actin was measured at 
the indicated time points and the relative p53 expression level was determined 
by dividing p53 by actin densitometry values. The value at the 0hr time point was 
set as one and the rest of the values at different time points were normalized 
against the 0 hr value. 
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greater than 6 fold and in the absence of K-Ras it was increased by greater than 2 fold.  
Similar results were obtained in A-549 cells where RalB depletion also increased the 
half-life of p53 from 30 min to 4 hours Figure 22. Depletion of K-Ras, RalA and RalB 
also increased the levels of mdm2, but in contrast to p53,  
it had little effect on its half-life (about 30 min with and without K-Ras, RalA and RalB 
siRNAs). This suggests that depletion of K-Ras, RalA or RalB stabilizes p53 which in 
turn induces the expression of mdm2, a known target for p53.  Consistent with this, the 
ability of RalB siRNA to increase mdm2 levels was rescued by p53 siRNA suggesting 
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Figure 22. Depletion of RalB increases p53 stability in A549 cells.  A. 
A549 cells were transfected with the indicated siRNA for 48hrs followed by 
cyclohexamide treatment for the indicated length of time and processed for 
western blot analysis as indicated in the material and method section. B.   
p53 and mdm2 from (A) were quantified as described under Figure 1S 
legend. C. A549 cells were transfected with the indicated siRNA for 48hrs 
and then processed for WB analysis.  Data are representative of 3 
independent experiments. 
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that RalB depletion up-regulates mdm2 expression in a p53-dependent manner Figure 
22).  Phosphorylation of p53 at ser-15 has been extensively used as a marker for stability 
of p53 
43, 44
.  Therefore we next determined the effects of RalA, RalB and K-Ras 
depletions on p53 Ser-15 phosphorylation.  Figure 20 shows that deletion of RalA and 
RalB in H460 cells resulted in increased p53 Ser-15 phosphorylation. Similar results 
were seen with A549 cells where depletion of RalB also increased p53 Ser15 
phosphorylation, Figure 22.    
Depletion of RalB inhibits cell cycle progression in a p53- and p21-dependent manner 
by decreasing the proportion of cells in S phase 
Cells exposed to DNA-damaging agents induce p53 which in turn induces, 
depending on the extent of the damage, either cell cycle arrest or apoptosis by regulating 
the transcription of specific genes 
39-42
 . Since p53 was induced and up-regulated p21 
expression following depletion of RalA, RalB or K-Ras, we next determined whether this 
increase in p53 has functional consequences on cell cycle progression. To this end, we 
transfected A549 cells with siRNA to K-Ras, RalA or RalB and processed the cells for 
cell cycle analysis as described under Experimental Procedures.  Figures 23 show that 
depletion of RalA had little effect on cell cycle progression.  In contrast, depletion of 
RalB decreased the percentage of cells in S-phase by 57% (Figure 23 and Table 3A) to 70 
% (Figure 23 and Table 3A) whereas K-Ras increased the percentage of cells in G2M 
phase by 4 to 6.7 fold (Figures 23/ Table 3A ).  To determine if these effects are p53-
dependent, we co-transfected the cells with siRNA to p53 along with siRNAs to either K-
Ras, RalA or RalB and determined the effects on cell cycle progression as described 
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under Experimental Procedures.  Figure 23 and Table 3A show that depletion of p53 
inhibited RalB and K-Ras siRNAs from affecting cell cycle progression.   
Since p21 is known to be up-regulated by p53 and to be involved in G1/S 
transition, we next determined if the p21 induction by p53 following depletion of RalB is 
required for RalB siRNA to decrease the percentage of cells in S phase. To this end, we 
co-transfected the cells with  
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Figure 23. Effects of Depletion of K-Ras, RalA and Ral B on cell cycle 
progression. A549 cells were treated with the indicated siRNA for 48 hrs and 
processed for cell cycle analysis as described in the Experimental Procedures 
section. The percentage of cells in each cell cycle phase relative to NT is shown. 
(A)  Depletion of P53 rescue. (B) Depletion of p21 rescue. 
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siRNA to p21 along with siRNAs to either K-Ras, RalA or RalB and determined the 
effects on cell cycle progression as described under Experimental Procedures.  Figure 23 
and Table 3B shows that, co-depletion of p21 completely rescued from the effects of 
RalB siRNA on cell cycle progression suggesting that the ability of RalB siRNA to 
decrease the proportion of cells in S phase depends on p53-induced p21. 
Table 3. Percent of cells at different phases of cell cycle. 
Effects of Depleting RalA and RalB on apoptosis 
As mentioned above another important function of p53 is to promote apoptosis.  
Furthermore, depletion of RalB but not RalA has been shown to induce apoptosis 
33
 but 
the molecular mechanism by which this occurs is not known.  Therefore, we next 
determined whether depletion of RalB induces apoptosis and whether this is p53-
dependent.  To this end, we transfected A549 and H460 cells with siRNA to K-Ras, RalA 
or RalB in the presence or absence of siRNA to p53 and processed the cells for western 
blotting and for Caspase 3 activation by a fluorescence assay as described under 
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Experimental Procedures.  Figure 24  shows that in A549 cells, depletion of K-Ras and 
RalB but not RalA induced apoptosis with K-Ras depletion having significantly higher 
effects (7-fold from 200 to 1400) than RalB depletion (3-fold from 200 to 600).  Figure 
24 also shows that siRNA to p53 inhibited K-Ras and RalB siRNA from inducing 
apoptosis.  These results suggest that depletion of K-Ras and RalB induced apoptosis by 
a p53-dependent mechanism in A549 cells.  In H460 cells, however, depletion of K-Ras 
but not that of RalA and RalB significantly induces apoptosis Figure 24, and depletion of 
p53 rescues apoptosis. 
Depletion of RalB and to a lesser extent RalA inhibits anchorage-independent growth 
and invasion in a p53-dependent manner 
The involvement of RalA and RalB in malignant transformation has been well 
documented 
45
.  While RalA is believed to be involved in promoting anchorage-
independent growth in soft agar, RalB is believed to promote invasion and migration, 
although this is cell type-dependent
28-32
.  Since p53 is a potent tumor suppressor, we 
reasoned that Ral proteins may affect some of these hallmarks of transformation in a p53-
dependent manner. To this end we depleted K-Ras, RalA or RalB in the presence or 
absence of p53 siRNA and processed the cells for soft agar and invasion assays as 
described under Experimental Procedures. Figure 25 shows that depleting K-Ras or RalB 
but not RalA inhibited soft agar growth of H460 and HCT116 cells.  The inhibition of 
soft agar growth following RalB depletion was rescued fully by siRNA to p53.  In 
contrast, siRNA to p53 only partially rescued from the inhibition of soft agar growth 
following K-Ras depletion.  Another critical hallmark of cancer is invasion; we therefore 
investigated the effects of depleting these 3 proteins on invasion. Figure 26 shows that 
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depletion of K-Ras, RalB and to a lesser extent RalA inhibited invasion of all 3 cell lines, 
A549, HCT116 and H460. Co-depletion with p53 rescued from this inhibition of invasion  
These results suggest that depletion of K-Ras, RalA and RalB requires p53 to inhibit 
invasion of A549, H460 and HCT116 cells.   
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Figure 24. Effects of depleting K-Ras, RalA and RalB on apoptosis.  H460 
and A549 cells were transfected with siRNA for 48 hrs and then harvested for 
western blot analysis (left panel) or caspase-3 activation assay (right panel) as 
described under Experimental Procedures. Data are representative of 2 
independent experiments. 
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Figure 25. Effects of Depletion of K-Ras, Ral A and Ral B on anchorage-
independent growth. H460 or HCT116 cells were transfected with the 
indicated siRNA for 48hrs before plating in soft agar as described in 
Experimental Procedures section. Results are shown as average % inhibition of 
four independent experiments (H460) or three independent experiments 
(HCT116). NT and NT+p53 siRNA were set as 100%. For H460 Mean number 
of colonies for NT was 323+/-8.5 and for NT+p53 siRNA was 232+/-66.22; and 
for HCT116 mean number of colonies for NT was 469 +/- 7.2 and for NT+p53 
siRNA was 484 +/- 6. Error bars show SE. Student t-test was used to compare 
the means; and p-values are shown for tests that show significant differences (*, 
p<0.05).  Top panel shows representative soft agar pictures for HCT116 cells  
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Discussion 
Among the three most studied downstream effector pathways of Ras, 
Raf/Mek/Erk, Pi3K/Akt and RalGDS/Ral, recently the latter has gained more attention as 
it has been shown to be more critical in mediating Ras-driven malignant transformation 
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Figure 26. Effects of Depletion of K-Ras, Ral A and Ral B on invasion.  
A549, H460 or HCT116 cells were transfected with the indicated siRNA for 48 
hrs, then equal number of cells were seeded for invasion assays as described in 
the material and method section. The cells were then photographed and counted 
to determine the mean number of invading cells. Top panel shows 
representative image of invading cells of H460, while bottom panels show 
average number of invading cells. P values for  H460 are K-Ras 0.02, RalA 0.02 
RalB 0.03.   P values for HCT116 are K-Ras 0.006, RalB 0.007.  P values for 
A549 are K-Ras 0.004 and RalB 0.0006) 
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in several cancers 
27, 46
.  Specifically RalA has been implicated in anchorage-independent 
growth whereas RalB has been implicated in apoptosis evasion, migration and invasion, 
although this is cell-type-dependent 
28-32, 39
 . The mechanism by which RalA and RalB 
mediate these effects is not well understood. Furthermore, mt K-Ras suppresses p53 
levels but it is not known which of its downstream effectors mediate this effect.  In this 
manuscript we have demonstrated that the expression of K-Ras, RalA and RalB but not c-
Raf and Akt1/2 is required for maintaining low levels of p53 in human cancer cells that 
harbor mt K-Ras and wt p53. The observation that depletion of K-Ras increased p53 
levels is novel and consistent with observation that K-Ras can suppress p53 levels 
16
.  
Indeed, while mt H-Ras and mt N-Ras were shown to induce p53 levels and senescence, 
mt K-Ras was shown to suppress p53 levels 
11, 14, 16-20
. Therefore, it is not surprising that, 
unlike cells that harbor mt H-Ras and mt N-Ras, many human cancer cells that harbor mt 
K-Ras also express wt p53, suggesting that mt K-Ras triggers pathways capable of 
overcoming the tumor suppressive activity of p53. Our studies suggest that RalA and 
RalB could be among those pathways that may be used by mt K-Ras to suppress p53 
levels. In contrast, pathways mediated by c-Raf and Akt1/2 do not appear to be required 
since their depletion did not increase p53 levels. While our studies demonstrated that 
depletion of Raf or Akt does not increase p53 levels, others have shown that forced 
expression of Raf or Akt induces p53 degradation
21, 22
. This suggests that while Raf and 
Akt can induce degradation of p53, their expression is not required to maintain low levels 
of p53 in some human cancer cells.  It is important to note that depletion of RalA and 
RalB increased p53 levels only in human cancers cells that harbor mt K-Ras and wt p53, 
suggesting that RalA and RalB may mediate the ability of mt K-Ras to suppress p53.  
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However, the fact that depletion of RalB was more potent at increasing the levels of p53 
than depletion of K-Ras (Figure 19) coupled with the fact that depletion of RalB and K-
Ras affected cell cycle progression differently (Figure 23) suggest that RalB may also 
regulate p53 in a K-Ras-independent manner. 
In addition to increasing p53 levels, depletion of RalA and RalB also increased 
the expression levels of p21 and mdm2 and decreased the expression levels of survivin, 
all 3 genes known to be transcriptionally-regulated by p53. The p53 siRNA rescue from 
these effects suggests that the ability of siRNA to RalA and RalB to increase p21 and 
mdm2 and to decrease survivin levels is dependent on their ability to increase the levels 
of p53.  This also indicates that the p53 induced following RalA or RalB depletion was 
functional and able to regulate the transcription of its target genes.  Furthermore, the 
ability of Ral siRNAs to regulate the expression of the p21, mdm2 and survivin genes in 
a p53-dependent manner has important consequences on the ability of Ral GTPases to 
contribute to malignant transformation (see more below).  In cells that lack both p53 
alleles such as Calu1 cells, depletion of RalA or RalB failed to affect p21 and survivin 
expression, further confirming the dependency of the Ral proteins on p53 to regulate the 
expression of these genes. Our results also suggest that K-Ras regulates the expression of 
p21 in a p53-dependent manner.  However, the effects of K-Ras depletion on survivin 
appear to be p53–independent in Calu-1 cells.  
Depletion of RalA and RalB as well as K-Ras resulted in a significant increase in 
its half life.  This increased p53 stability is specific in that depletion of K-Ras, RalA and 
RalB increased the mdm2 protein levels with little affects on its half life.  Consistent with 
this, depletion of RalA and RalB resulted in an increase in the levels of p53 Ser-15 
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phosphorylation which has been associated with p53 stability
43, 44
.  Taken together, these 
observations suggest that depletion of RalA and RalB results in increased p53 Ser-15 
phosphorylation and a more stable p53 that was able to induce the expression of p21 and 
mdm2 and down regulate the expression of survivin.  Depletion of these GTPases could 
also affect other phosphorylation sites on p53 that affect its stability. Indeed, cellular 
stress and DNA damage induce p53 phosphorylation at Ser-15 as well as Ser-20 and Ser-
37 which affect p53 stability by preventing its ubiquitination and degradation 
43, 44
. 
Therefore, investigations determining the effects of RalA and/or RalB depletion on p53 
post-translational modifications other than Ser-15 are warranted to further understand the 
mechanism by which depletion of RalA and RalB stabilizes p53.  Finally, mt K-Ras was 
shown to decrease the stability of p53 by activating the E3 ligase SNAIL which 
ubiquitinates p53 and targets it to proteasomal degradation 
16
.  It is therefore possible that 
depletion of RalA and/or RalB inhibits SNAIL as well as mdm2 E3 ligases leading to less 
ubiquitination of p53.   
The effects of depletion of the Ral GTPases on anchorage-dependent and -
independent growth, invasion, apoptosis and proliferation have previously been studied 
29, 33
. However, the mechanisms involved are not known and the contribution of p53 to 
these effects is not known.  Here we show that depletion of RalB inhibited cell cycle 
progression by decreasing the proportion of cells reaching S phase and by increasing the 
proportion of cells in both G1 and G2/M phases of the cell cycle.  The ability of RalB 
depletion to decrease the proportion of cells in S phase is rescued by p53 siRNA as well 
as p21 siRNA suggesting that RalB depletion induces p53 and p21 which contribute to 
inhibition of cell cycle progression.  Furthermore, depletion of K-Ras induces G2/M cell 
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cycle arrest in a p53-independent manner.  Therefore, the fact that depletions of K-Ras or 
RalB resulted in an increase in p53 levels, yet the consequences on cell cycle progression 
were different suggest that, in addition to affecting common genes such p53, each 
specific depletion also differentially affected other genes.  This is not surprising as it is 
known that Ral GTPases are regulated in a Ras-dependent and -independent manner, and 
that RalA and RalB themselves mediate different cellular effects.  In addition to the cell 
cycle effects, depletion of RalB and to a lesser degree RalA inhibits anchorage-
independent tumor cell growth and invasion which were also rescued by p53 siRNA.  
This suggests that in the absence of RalB the stabilized p53 is not only able to inhibit cell 
cycle progression and to inhibit invasion but also contributes to inhibition of anchorage-
independent tumor cell growth. Unlike cell cycle progression, depletion of K-Ras induces 
apoptosis and inhibits anchorage-independent tumor cell growth and invasion in a p53-
dependent manner.  
In summary, we have uncovered a novel molecular mechanism by which Ral 
GTPases affect transformation.  Furthermore, we have provided a biochemical link 
between Ral GTPases and the tumor suppressor p53 by demonstrating that the expression 
of Ral GTPases is required for maintaining low levels of p53, and that down regulation of 
the Ral proteins results in the stabilization and reactivation of p53. 
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Chapter 5 
Summary and Conclusions 
K-Ras and Ral GTPases have been extensively studied for their role in driving 
malignant transformation and maintaining various malignant phenotypes. Similarly, 
down regulation of the tumor suppressor p53 and up regulation of the anti-apoptotic 
protein survivin are prevalent in human cancer and contribute to various malignant 
phenotypes. In this thesis, we investigated the role of K-Ras, RalA and RalB GTPases in 
the regulation of survivin and p53 and the functional consequence of this regulation.  
First, we demonstrated that the expression of K-Ras is required for the 
maintenance of the high survivin levels in human cancer cell lines that harbor mutant K-
Ras but not in human cancer cell lines that express wild type Ras. This observation was 
made in cancer cell lines from different lineages, suggesting that the involvement of K-
Ras in survivin regulation is mutation- but not tissue-specific.  Knocking down K-Ras 
expression not only reduced the basal levels of survivin but it also inhibited drug-induced  
survivin, suggesting that K-Ras may mediate resistance to apoptotic or anti-proliferative 
drugs partly by up-regulating the expression of anti-apoptotic proteins such as survivin.  
While depletion of K-Ras reduced survivin levels, ectopic expression of 
constitutive active (CA) K-Ras failed to induce survivin levels. This is somewhat counter 
intuitive but it suggested that while the expression of K-Ras is required for maintaining 
high levels of survivin, mutant K-Ras alone is not sufficient to drive the expression of 
survivin. Though additional studies are required to reach a definitive conclusion, we 
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speculate that one possible reason for this is that the cancer cell lines as well as the 
immortalized cell lines that we used in these experiments already harbor many genetic 
alterations, and that ectopic expression of CA K-Ras was unable to further increase the 
levels of survivin. For example, the HPNE cells that were used in this project were 
immortalized by hTERT and E6/E7/st, which are known to antagonize p53, and induce 
the expression of survivin.  The other possible explanation is that mutant K-Ras is one of 
several  key nodes of complex signaling networks that are all required for maintaining 
high survivin levels in cancer cells.  Therefore, removing one of the nodes such as 
depleting K-Ras would compromise the integrity of the network and lead to reduction in 
survivin levels.  Consistent with explanation are recent studies that show that only co-
expression of K-Ras with β-catenin was able to induce survivin expression. Therefore, we 
conclude that mutant K-Ras is required for maintaining high survivin levels, but alone is 
not sufficient to drive survivin expression.  
Our studies also demonstrated that in T24 cells, a human bladder cancer cell line 
with mutant H-Ras, depletion of H-Ras reduced survivin expression. In contrast, 
depletion of H-Ras in the human breast cancer MDA-MB-468 cells that do not harbor 
mutant Ras did not reduce the levels of survivin.  The limited number of cell lines used 
precludes making generalized conclusion but it appears that mutant H-Ras may also be 
involved in the regulation of survivin. These results warrant further investigation to 
determine whether only mutant H-Ras and mutant K-Ras are required for the 
maintenance of high survivin levels, and whether reduction in survivin levels could be 
used as a read out or surrogate biomarker to measure inhibition of mutant H- Ras and 
mutant K-Ras. 
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Our studies also demonstrated that the reduction in survivin levels following 
depletion of K-Ras was rescued by the proteasome inhibitor bortezomib. This suggested 
that the depletion of K-Ras leads to the proteasome degradation of survivin. The 
mechanism by which depletion of K-Ras leads to proteasome mediated degradation of 
survivin is not clear. We first reasoned that depletion of K-Ras might affect survivin 
phosphorylation at Thr-34 and/or Ser-20 and leads to proteasome degradation. 
Phosphorylation of survivin at Ser-20 has been shown to interfere with the binding of 
XIAP to survivin. Since XIAP binding to survivin has been suggested to stabilize 
survivin, we speculated that depletion of K-Ras might increase Ser-20 phosphorylation 
and hence decrease the stability of survivin by interfering with the binding of XIAP to 
survivin. Similarly, dephoshorylation of survivin at Thr-34 has been shown to reduce the 
stability of survivin. We generated S20A, S34A and S20A/S34A non-phosphorylatable 
survivin mutants as well as S20D, S34D and S20D/S34D phospho-mimic survivin 
mutants and demonstrated that depletion of K-Ras was as efficient at reducing the levels 
of all these mutants as it was at reducing wild type survivin levels (data not shown). 
These results suggest that the ability of K-Ras depletion to decrease the stability of 
survivin may not depend on the phosphorylation of survivin at Thr-34 and/or Ser-20. 
Depletion of K-Ras has been shown to induce apoptosis in many, but not all, 
cancer cell line that harbor mutant K-Ras. Furthermore, in one study using the HCT-116 
isogenic colon cancer cell lines with and without mutant K-Ras, depletion of survivin 
resulted in induction of apoptosis and cell cycle arrest selectively in the isogenic cell line 
that harbors mutant K-Ras. We found that the presence of mutant K-Ras does not predict 
that depletion of survivin will result in apoptosis.  For example, while depletion of 
129 
 
survivin induced apoptosis in A549 and H460 cells it fail to produce similar effect in 
panc-1, miapaca-1 or sw1990 cells, yet all of these cell lines harbor mutant K-Ras.  
Furthermore, depletion of K-Ras decreases the levels of survivin and induced apoptosis 
in panc-1 as well as miapaca-2 cells. Yet, in these cell lines depletion of survivin itself 
does induce apoptosis, suggesting that the decrease in survivin levels does not contribute 
to apoptosis induction following K-Ras depletion in panc-1 and miapaca-2 cell lines. We 
found that depletion of K-Ras also reduced the levels of XIAP, and this may contribute to 
the induction of apoptosis following K-Ras depletion. Pro- or anti-apoptotic members of 
the Bcl2 family do not appear to be involved since their levels were not affected by 
depletion of K-Ras. Future study using gene expression profiling or proteomics that focus 
on other survival and apoptotic proteins could give further insight about the molecular 
mechanism by which depletion of K-Ras induces apoptosis. 
Although survivin was dispensable for apoptosis in some human cancer cell lines, 
we have showed that it plays critical role in other K-Ras-driven malignant phenotypes. 
To this end, reduction of survivin following depletion of K-Ras might be beneficial to 
inhibit K-Ras-driven invasion and metastasis, therefore future studies are warranted to 
study the role of survivin inhibitors at inhibiting K-Ras driven malignant phenotypes. 
While K-Ras has been shown to have multiple downstream effectors, the three 
canonical downstream effectors Raf/Mek/Erk, Pi3K/Akt and RalGDS/Ral have been 
extensively studied for their role in Ras-driven malignant transformation. Our studies 
demonstrated that depletion of RalA and/or RalB but not Akt1/2 or Raf-1 decreased the 
levels of survivin, and this suggested that Ral proteins may mediate the effects of K-Ras 
on survivin. While the presence of mutant K-Ras in a human cancer cell line predicted 
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whether depletion of K-Ras would result in decreased survivin levels, mutation of K-Ras 
alone was not sufficient to predict the same for Ral protein depletion. We found that both 
mutant K-Ras and wild type p53 are required for Ral depletion to result in decreased 
survivin. This suggested that Ral regulation of survivin could be mediated by p53. In 
deed, in H460 and A549 cells, co-depletion with p53 prevented the decrease in survivin 
levels following RalA and/or RalB depletion.  This is an important finding that not only 
gave evidence that the ability of Ral proteins to regulate survivin may depend on p53, but 
it also suggested a novel role for Ral as a potential regulator of p53. Our follow up 
studies gave further support to this suggestion (see more below).   
Although depletion of Ral A and Ral B individually did not affect the levels of 
survivin in certain cells (wt Ras and/or mt p53), it is possible that the combined depletion 
of Ral A and Ral B may affect survivin levels. Studies have shown that depletion of RalA 
induces activation of RalB and vice-versa.  Therefore, a compensatory mechanism could 
be responsible for the lack of effect on the survivin levels when the Ral proteins are 
depleted individually. 
We also found that depletion of Akt1/2 or c-Raf by siRNA was unable to reduce 
survivin levels suggesting that the Pi3K/Akt1/2 and c-Raf/Mek/Erk pathways are not 
required for maintaining high survivin levels. However, it is important to point out that 
Pi3K could still be involved since it is upstream of Akt1/2 and it has additional effecter 
than Akt1/2.  Therefore use of siRNA to Pi3K may help to delineate if Pi3K is required 
for maintaining survivin levels in mutant K-Ras harboring cells. In contrast to this, since 
we saw reduction of Erk activation following depletion of c-Raf, we believe that the 
Raf/Mek/Erk pathway is not required to maintain high levels of survivin. 
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Our studies that demonstrated that the decreased survivin levels following Ral 
depletion required the expression of p53 (see above) suggested that Ral proteins may 
regulate p53 levels.  Indeed, we have found that depletion of Ral GTPases increases the 
levels of p53 and this is majorly by affecting the stability of the protein. RalA and/or 
RalB depletion leads to significant increase in the half-life of p53 as well as 
phosphorylation of p53 at Ser-15. Phosphorylation of p53 has been used as a marker of 
p53 stability and we believe that Ral GTPase may affect the stability of p53 by affecting 
this phosphorylation site. While we used Ser-15 as a marker, our studies do not rule out 
the possibility of other phosphorylation sites and other post-translational modifications 
that are known to affect p53 stability. Therefore, future studies that investigate how 
depletion of Ral proteins leads to increased p53 protein stability could give further insight 
about the molecular mechanism.  
The depletion of the Ral proteins resulted in increased levels of p53, and this p53 
appears to be functional, as demonstrated by modulation of its target genes p21 and 
survivin.  Indeed, depletion of Ral proteins led to increased expression of p21 and 
decreased expression of survivin in a p53-dependent manner. Depletion of RalA and/or 
RalB increased p53 levels in some cell lines more than did the depletion of K-Ras. 
Furthermore, functionally while depletion of K-Ras interfered with cell cycle progression 
at G2/M in a p53- independent manner, depletion of RalB affect cell cycle progression at 
S phase in a p53-dependent manner. Therefore, we conclude that Ral GTPase may 
regulate the levels of p53 in a K-Ras-independent manner in addition to K-Ras-
independent manner. 
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In this thesis, we also showed that depletion of Ral GTPases inhibited anchorage-
independent growth and invasion in p53-dependent manner.  Despite previous studies 
that showed the importance of RalA but not RalB in anchorage-independent growth and 
in-vivo tumor formation, in our studies we found anchorage-independent growth to be 
potently inhibited in cells where RalB was depleted.  Finally, We have recently shown 
that ectopic expression of CA K-Ras V12, RalA 72L and RalB 72L down regulated the 
expression of ectopically expressed p53 and inhibited its ability to up regulate the 
transcriptional activation of the promoter of its target gene p21 in normal mouse embryo 
fibroblasts.  In contrast, ectopic expression of constitutive active RalB 72L in A549 cells 
that already harbor mutant K-Ras, failed to reduce p53 levels (data not shown).  
In summary, in this thesis we have provided evidence that some human cancer 
cells require the expression of K-Ras and Ral GTPases to maintain high levels of survivin 
and low levels of p53, and this appears to be mediated at least in part by mechanisms that 
regulate the stability of both survivin and p53.  Using several human cancer cell lines 
from different lineages, we have discovered that in cells that harbor mt K-Ras and WT 
p53, down regulation of K-Ras, RalA, RalB but not c-Raf and Akt1/2 leads to p53 Ser15 
phosphorylation and a significant increase in its half life and stability as well as 
regulation of p53 target genes (i.e. p21, mdm2, survivin) and inhibition of cell cycle 
progression, soft agar growth and invasion.  Our data suggest that K-Ras and Ral 
GTPases suppress p53 levels and their depletion increases p53 stability and reactivates it 
to suppress malignant transformation.  The following working model for the role of K-
Ras and Ral in the maintenance of survivin and p53 protein levels is proposed.  
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Figure 27. Role of K-Ras, RalA and RalB in the regulation of p53 
and survivin. In cancer cells that harbor wt-Ras, regardless of the 
mutation status of p53, depleting K-Ras, RalA or RalB by siRNA fails to 
affect the protein levels of p53 or survivin. In cells that harbor mt-K-Ras 
and mt-p53, depleting K-Ras reduces survivin protein levels but fails to 
affect the levels of p53. On the other hand, in mt-K-Ras/wt p53 
harboring cells, depleting RalA, RalB or K-Ras induces p53 and reduces 
survivin protein levels. 
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